

Section XXXII  
Adolescent and Young Adult Cancer by Site  
Incidence, Survival and Mortality

Tumors affecting adolescents and young adults often differ from those affecting pediatric and older adult populations (1). For this reason, a classification scheme has been proposed for tumors diagnosed in adolescents and young adults (2). This classification scheme was updated based on site and histology codes of the International Classification of Diseases for Oncology, Third Edition (3). Effective 2001, all cases reported to SEER were required to have an ICD-O-3 histology and behavior code and all previous cases were converted to ICD-O-3 (4). In addition, although benign brain tumors have also been reported to SEER since 2004, not enough time has elapsed to present rates and trend data for these tumors. These site / histology groupings, however, are not comparable with the groupings of ICD-10 for mortality. Therefore, for incidence and mortality comparisons, the SEER site recode as described in the appendix was used (5). In this chapter, the incidence of malignant cancers in adolescent and young adults, 15 to 39 years of age, are presented based on the 2 different classification schemes described above.

REFERENCES:

1. The distinctive biology of cancer in adolescents and young adults. Bleyer A, Barr R, Hayes-Lattin B, et al. *Nat Rev Cancer*. 2008; 8: 288-98.
2. Barr RD, Holowaty EJ, Birch JM. Classification schemes for tumors diagnosed in adolescents and young adults. *Cancer* 2006; 106: 1425-1430.
3. International Classification of Diseases for Oncology, Third Edition Edited by A. Fritz, C. Percy, A. Jack, K. Shanmugaratnam, L. Sobin, D.M. Parkin and S. Whelan. World Health Organization. Geneva, Switzerland, 2000. 240 pp.
4. National Cancer Institute SEER Conversion Programs.  
Worldwide web: (<http://seer.cancer.gov/tools/conversion/>) Accessed May 28, 2008.
5. National Cancer Institute Cancer Statistics Review 1975-2005. Appendix.  
Worldwide web: ([http://seer.cancer.gov/csr/1975\\_2005/results\\_merged/topic\\_siterecode.pdf](http://seer.cancer.gov/csr/1975_2005/results_merged/topic_siterecode.pdf))  
Accessed May 28, 2008.

Table XXXII-1

AGE-ADJUSTED SEER INCIDENCE<sup>a</sup>, BY AGE GROUP AND SEX  
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>  
All Races, 2001-2005

Site	Ages 0-14		Ages 15-39		Ages 40+	
	Male	Female	Male	Female	Male	Female
All Sites Combined	16.1	14.1	51.1	79.5	1226.4	882.5
1. LEUKEMIAS	5.4	4.5	3.4	2.3	31.6	17.9
1.1 Acute lymphoid leukemia	4.3	3.6	1.2	0.6	1.2	1.0
1.2 Acute myeloid leukemia	0.9	0.7	1.2	1.1	9.8	6.1
1.3 Chronic myeloid leukemia	0.0	0.0	0.6	0.4	2.7	1.7
1.4 Other and unspecified leukemias	0.2	0.2	0.4	0.2	18.0	9.1
2. LYMPHOMAS	1.8	1.0	8.6	6.8	53.6	37.5
2.1 Non-Hodgkin Lymphoma	1.2	0.6	4.9	3.1	49.8	35.0
2.2 Hodgkin Lymphoma	0.7	0.4	3.6	3.7	3.8	2.5
3. CNS, INTRACRANIAL, INTRASPINAL	3.2	2.9	3.1	2.6	13.5	9.0
3.1 Astrocytoma	1.5	1.5	1.7	1.3	10.4	6.5
3.1.1 Specified low-grade astrocytic tumors	1.1	1.1	0.4	0.4	0.3	0.2
3.1.2 Glioblastoma and anaplastic astrocytoma	0.2	0.2	0.8	0.6	9.3	5.8
3.1.3 Astrocytoma, NOS	0.3	0.2	0.4	0.3	0.7	0.5
3.2 Other glioma	0.5	0.5	0.9	0.8	1.6	1.2
3.3 Ependymoma	0.3	0.3	0.2	0.2	0.3	0.3
3.4 Medulloblastoma and other PNET	0.8	0.5	0.3	0.2	0.1	0.1
3.4.1 Medulloblastoma	0.4	0.3	0.1	0.1	0.0	-
3.4.2 Supratentorial PNET	0.3	0.2	0.1	0.1	0.1	0.0
3.5 Other specified intracranial and intraspinal neoplasms	0.1	0.1	0.1	0.1	0.3	0.4
3.6 Unspecified intracranial and intraspinal neoplasms	-	-	0.1	0.0	0.7	0.6
4. OSSEOUS & CHONDROMATOUS NEOPLASMS	0.8	0.8	1.1	0.8	1.4	1.0
4.1 Osteosarcoma	0.4	0.4	0.5	0.3	0.3	0.2
4.2 Chondrosarcoma	0.0	-	0.2	0.2	0.7	0.5
4.3 Ewing tumor	0.3	0.3	0.3	0.2	0.1	0.1
4.4 Other specified and unspecified bone tumors	-	-	0.1	0.1	0.3	0.2
5. SOFT TISSUE SARCOMAS	1.1	0.9	3.6	2.2	12.3	8.9
5.1 Fibromatous neoplasms	0.2	0.1	0.7	0.8	3.5	2.1
5.2 Rhabdomyosarcoma	0.6	0.5	0.2	0.1	0.2	0.2
5.3 Other specified soft tissue sarcoma	0.3	0.3	2.6	1.4	8.7	6.6
5.3.1 Specified soft tissue sarcoma	0.2	0.2	2.4	1.1	7.0	5.3
5.3.1.1 Specified (excluding Kaposi sarcoma)	0.2	0.2	1.1	1.1	5.1	5.1
5.3.1.2 Kaposi sarcoma	-	-	1.3	0.0	1.9	0.2
5.3.2 Unspecified soft tissue sarcoma	0.1	0.1	0.3	0.2	1.8	1.3
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	0.5	0.6	10.3	1.0	4.2	0.2
6.1 Germ cell and trophoblastic neoplasms of gonads	0.2	0.3	9.7	0.7	4.0	0.1
6.2 Germ cell and trophoblastic neoplasms of nongonadal sites	0.3	0.3	0.5	0.3	0.2	0.1
6.2.1 Intracranial sites	0.2	0.1	0.2	0.0	-	-
6.2.2 Other nongonadal sites	0.1	0.2	0.4	0.3	0.2	0.1

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table XXXII-1 - continued

AGE-ADJUSTED SEER INCIDENCE<sup>a</sup>, BY AGE GROUP AND SEX  
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>  
All Races, 2001-2005

Site	Ages 0-14		Ages 15-39		Ages 40+	
	Male	Female	Male	Female	Male	Female
7. MELANOMA AND SKIN CARCINOMAS	0.2	0.3	5.8	9.4	58.0	32.3
7.1 Melanoma	0.2	0.2	5.6	9.3	54.5	30.4
7.2 Skin carcinomas	-	-	0.1	0.1	3.5	1.9
8. CARCINOMAS (excluding skin)	0.3	0.6	14.3	52.9	993.6	732.0
8.1 Thyroid carcinoma	0.1	0.3	2.5	12.4	8.6	20.5
8.2 Other carcinoma of head and neck	0.1	0.1	1.7	1.4	50.6	16.7
8.2.1 Nasopharyngeal carcinoma	0.0	-	0.3	0.2	1.9	0.7
8.2.2 Other sites in lip, oral cavity and pharynx	-	0.1	1.2	1.0	32.2	12.1
8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck	-	-	0.3	0.2	16.6	3.9
8.3 Carcinoma of trachea, bronchus, and lung	-	-	1.1	1.3	171.6	113.4
8.4 Carcinoma of breast	-	-	0.1	20.0	2.6	272.6
8.5 Carcinoma of genitourinary tract	0.0	0.1	2.7	10.7	501.8	109.2
8.5.1 Carcinoma of kidney	-	0.0	1.5	1.1	37.1	17.9
8.5.2 Carcinoma of bladder	-	-	0.9	0.4	85.0	21.1
8.5.3 Carcinoma of gonads	-	-	0.0	-	0.0	-
8.5.4 Carcinoma of cervix and uterus	-	-	-	8.8	-	60.5
8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract	-	-	0.3	0.4	379.6	9.6
8.6 Carcinoma of gastrointestinal tract	0.1	0.1	5.6	4.6	236.7	154.6
8.6.1 Carcinoma of colon and rectum	-	-	3.5	3.1	135.3	100.8
8.6.2 Carcinoma of stomach	-	-	0.7	0.6	24.2	11.3
8.6.3 Carcinoma of liver and intrahepatic bile ducts	-	0.0	0.5	0.2	21.1	7.2
8.6.4 Carcinoma of pancreas	-	-	0.4	0.3	26.6	20.6
8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract	-	-	0.5	0.3	29.5	14.7
8.7 Carcinoma of other and ill-defined sites, NOS	-	0.1	0.6	2.5	21.6	45.1
8.7.1 Adrenocortical carcinoma	-	-	0.0	0.1	0.3	0.3
8.7.2 Carcinoma of other and ill-defined sites, NOS	-	-	0.6	2.4	21.3	44.9
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	2.8	2.6	0.7	1.1	24.7	19.6
9.1 Other pediatric and embryonal tumors, NOS	2.6	2.4	0.1	0.1	0.2	0.1
9.1.1 Wilms tumor	0.6	0.7	-	-	-	0.0
9.1.2 Neuroblastoma	1.0	1.0	0.0	-	-	-
9.1.3 Other pediatric and embryonal tumors, NOS	1.0	0.7	0.1	0.0	0.2	0.1
9.2 Other specified neoplasms, NOS	0.1	0.2	0.6	1.0	24.5	19.4
9.2.1 Paraganglioma and glomus tumors	-	-	0.0	0.0	0.1	0.1
9.2.2 Other specified gonadal tumors	-	-	0.0	0.1	0.0	0.4
9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS	0.1	0.1	0.4	0.3	17.5	11.2
9.2.4 Other specified neoplasms, NOS <sup>c</sup>	-	-	0.2	0.6	6.9	7.8
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	0.3	0.4	33.5	24.1

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

<sup>c</sup> Myeloproliferative disorders and myelodysplastic syndromes were first reported effective January 1, 2001 with the implementation of ICD-O 3.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table XXXII-2

AGE-ADJUSTED SEER INCIDENCE<sup>a</sup>, BY AGE GROUP AND SEX  
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>  
White, 2001-2005

Site	Ages 0-14		Ages 15-39		Ages 40+	
	Male	Female	Male	Female	Male	Female
All Sites Combined	17.0	14.8	54.3	83.3	1228.1	908.3
1. LEUKEMIAS	5.8	4.8	3.6	2.4	33.0	18.6
1.1 Acute lymphoid leukemia	4.7	3.9	1.4	0.6	1.2	1.0
1.2 Acute myeloid leukemia	0.9	0.7	1.2	1.1	10.1	6.3
1.3 Chronic myeloid leukemia	-	-	0.6	0.4	2.7	1.7
1.4 Other and unspecified leukemias	0.2	0.1	0.4	0.3	19.0	9.6
2. LYMPHOMAS	1.9	1.1	8.8	7.1	55.9	39.4
2.1 Non-Hodgkin Lymphoma	1.2	0.6	4.9	3.1	51.9	36.8
2.2 Hodgkin Lymphoma	0.7	0.5	3.9	4.0	4.0	2.7
3. CNS, INTRACRANIAL, INTRASPINAL	3.5	3.0	3.4	2.9	14.8	9.9
3.1 Astrocytoma	1.6	1.6	1.9	1.5	11.5	7.3
3.1.1 Specified low-grade astrocytic tumors	1.2	1.2	0.5	0.4	0.4	0.3
3.1.2 Glioblastoma and anaplastic astrocytoma	0.2	0.2	0.9	0.7	10.3	6.4
3.1.3 Astrocytoma, NOS	0.3	0.3	0.4	0.4	0.8	0.6
3.2 Other glioma	0.6	0.5	1.0	0.9	1.8	1.3
3.3 Ependymoma	0.3	0.2	0.2	0.2	0.4	0.3
3.4 Medulloblastoma and other PNET	0.9	0.5	0.3	0.2	0.1	0.1
3.4.1 Medulloblastoma	0.5	0.3	0.1	0.1	0.0	-
3.4.2 Supratentorial PNET	0.4	0.2	0.2	0.1	0.1	0.0
3.5 Other specified intracranial and intraspinal neoplasms	0.1	0.1	0.1	0.1	0.3	0.3
3.6 Unspecified intracranial and intraspinal neoplasms	-	-	0.1	0.0	0.7	0.6
4. OSSEOUS & CHONDROMATOUS NEOPLASMS	0.8	0.8	1.1	0.9	1.5	1.1
4.1 Osteosarcoma	0.4	0.4	0.5	0.3	0.3	0.2
4.2 Chondrosarcoma	-	-	0.2	0.2	0.7	0.5
4.3 Ewing tumor	0.4	0.3	0.3	0.3	0.1	0.1
4.4 Other specified and unspecified bone tumors	-	-	0.1	0.1	0.3	0.2
5. SOFT TISSUE SARCOMAS	1.0	0.9	3.3	2.1	12.5	8.8
5.1 Fibromatous neoplasms	0.2	0.1	0.7	0.7	3.5	2.1
5.2 Rhabdomyosarcoma	0.6	0.5	0.2	0.1	0.2	0.1
5.3 Other specified soft tissue sarcoma	0.3	0.3	2.4	1.3	8.8	6.6
5.3.1 Specified soft tissue sarcoma	0.2	0.2	2.1	1.1	7.0	5.3
5.3.1.1 Specified (excluding Kaposi sarcoma)	0.2	0.2	1.1	1.1	5.3	5.1
5.3.1.2 Kaposi sarcoma	-	-	1.0	-	1.7	0.2
5.3.2 Unspecified soft tissue sarcoma	0.1	0.1	0.2	0.2	1.8	1.3
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	0.6	0.6	12.2	1.0	4.8	0.2
6.1 Germ cell and trophoblastic neoplasms of gonads	0.2	0.3	11.6	0.7	4.7	0.1
6.2 Germ cell and trophoblastic neoplasms of nongonadal sites	0.4	0.3	0.5	0.3	0.2	0.1
6.2.1 Intracranial sites	0.2	0.1	0.2	0.0	-	-
6.2.2 Other nongonadal sites	0.1	0.2	0.4	0.3	0.2	0.1

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table XXXII-2 - continued

AGE-ADJUSTED SEER INCIDENCE<sup>a</sup>, BY AGE GROUP AND SEX  
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>  
White, 2001-2005

Site	Ages 0-14		Ages 15-39		Ages 40+	
	Male	Female	Male	Female	Male	Female
7. MELANOMA AND SKIN CARCINOMAS	0.2	0.3	6.9	11.5	66.5	37.6
7.1 Melanoma	0.2	0.3	6.7	11.4	62.7	35.6
7.2 Skin carcinomas	-	-	0.1	0.1	3.8	2.0
8. CARCINOMAS (excluding skin)	0.3	0.7	14.1	54.0	982.1	750.0
8.1 Thyroid carcinoma	0.1	0.4	2.7	13.4	9.1	21.3
8.2 Other carcinoma of head and neck	0.1	0.1	1.6	1.2	51.0	16.8
8.2.1 Nasopharyngeal carcinoma	-	-	0.1	0.1	1.2	0.4
8.2.2 Other sites in lip, oral cavity and pharynx	-	0.1	1.2	1.0	33.4	12.4
8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck	-	-	0.3	0.2	16.4	4.0
8.3 Carcinoma of trachea, bronchus, and lung	-	-	1.0	1.3	171.4	118.3
8.4 Carcinoma of breast	-	-	0.0	19.8	2.6	283.2
8.5 Carcinoma of genitourinary tract	-	0.1	2.8	11.3	496.1	113.5
8.5.1 Carcinoma of kidney	-	-	1.5	1.1	38.1	18.6
8.5.2 Carcinoma of bladder	-	-	1.0	0.5	92.4	22.6
8.5.3 Carcinoma of gonads	-	-	0.0	-	0.0	-
8.5.4 Carcinoma of cervix and uterus	-	-	-	9.2	-	62.3
8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract	-	-	0.3	0.5	365.5	10.0
8.6 Carcinoma of gastrointestinal tract	0.1	0.1	5.2	4.4	230.0	149.7
8.6.1 Carcinoma of colon and rectum	-	-	3.4	3.0	134.8	99.7
8.6.2 Carcinoma of stomach	-	-	0.7	0.5	21.5	9.6
8.6.3 Carcinoma of liver and intrahepatic bile ducts	-	-	0.3	0.2	17.6	6.0
8.6.4 Carcinoma of pancreas	-	-	0.3	0.4	26.5	20.1
8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract	-	-	0.5	0.3	29.5	14.2
8.7 Carcinoma of other and ill-defined sites, NOS	-	0.1	0.5	2.5	21.9	47.1
8.7.1 Adrenocortical carcinoma	-	-	0.0	0.1	0.3	0.3
8.7.2 Carcinoma of other and ill-defined sites, NOS	-	-	0.5	2.4	21.6	46.8
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	2.8	2.7	0.7	1.0	24.1	18.4
9.1 Other pediatric and embryonal tumors, NOS	2.7	2.5	0.1	0.1	0.2	0.2
9.1.1 Wilms tumor	0.7	0.7	-	-	-	-
9.1.2 Neuroblastoma	1.1	1.1	0.0	-	-	-
9.1.3 Other pediatric and embryonal tumors, NOS	1.0	0.7	0.1	0.0	0.2	0.1
9.2 Other specified neoplasms, NOS	0.1	0.2	0.6	0.9	23.9	18.2
9.2.1 Paraganglioma and glomus tumors	-	-	-	0.0	0.1	0.1
9.2.2 Other specified gonadal tumors	-	-	-	0.1	0.0	0.3
9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS	0.1	0.1	0.3	0.2	16.6	10.3
9.2.4 Other specified neoplasms, NOS <sup>c</sup>	-	-	0.2	0.6	7.1	7.5
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	0.3	0.4	33.0	24.4

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

<sup>c</sup> Myeloproliferative disorders and myelodysplastic syndromes were first reported effective January 1, 2001 with the implementation of ICD-O 3.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table XXXII-3

AGE-ADJUSTED SEER INCIDENCE<sup>a</sup>, BY AGE GROUP AND SEX  
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>  
Black, 2001-2005

Site	Ages 0-14		Ages 15-39		Ages 40+	
	Male	Female	Male	Female	Male	Female
All Sites Combined	11.9	11.1	40.9	66.9	1474.2	866.2
1. LEUKEMIAS	3.2	2.6	3.0	2.0	26.0	15.5
1.1 Acute lymphoid leukemia	2.0	1.7	0.7	0.5	0.9	1.0
1.2 Acute myeloid leukemia	0.9	0.6	1.2	0.9	7.7	5.3
1.3 Chronic myeloid leukemia	-	-	0.7	0.4	3.0	1.8
1.4 Other and unspecified leukemias	-	-	0.4	0.3	14.5	7.4
2. LYMPHOMAS	1.5	1.1	9.6	7.1	40.6	27.0
2.1 Non-Hodgkin Lymphoma	1.0	0.6	6.6	4.0	36.8	24.6
2.2 Hodgkin Lymphoma	0.6	0.5	3.1	3.1	3.9	2.4
3. CNS, INTRACRANIAL, INTRASPINAL	2.2	2.4	1.7	1.4	8.2	5.8
3.1 Astrocytoma	1.0	1.0	1.0	0.7	5.6	3.4
3.1.1 Specified low-grade astrocytic tumors	0.6	0.7	0.2	0.2	-	-
3.1.2 Glioblastoma and anaplastic astrocytoma	-	-	0.5	0.3	5.0	2.9
3.1.3 Astrocytoma, NOS	-	-	0.3	0.2	0.5	0.4
3.2 Other glioma	0.5	0.5	0.4	0.4	0.9	0.8
3.3 Ependymoma	-	0.3	-	-	0.2	-
3.4 Medulloblastoma and other PNET	0.4	0.4	-	-	-	-
3.4.1 Medulloblastoma	-	-	-	-	-	-
3.4.2 Supratentorial PNET	-	-	-	-	-	-
3.5 Other specified intracranial and intraspinal neoplasms	-	-	-	-	0.6	0.6
3.6 Unspecified intracranial and intraspinal neoplasms	-	-	-	-	0.8	0.8
4. OSSEOUS & CHONDROMATOUS NEOPLASMS	0.4	0.7	0.9	0.5	1.0	0.9
4.1 Osteosarcoma	0.4	0.6	0.6	0.4	0.3	0.4
4.2 Chondrosarcoma	-	-	-	-	0.4	0.3
4.3 Ewing tumor	-	-	-	-	-	-
4.4 Other specified and unspecified bone tumors	-	-	-	-	0.2	-
5. SOFT TISSUE SARCOMAS	1.3	1.0	6.6	3.2	11.9	10.9
5.1 Fibromatous neoplasms	-	-	1.0	1.2	2.8	2.5
5.2 Rhabdomyosarcoma	0.6	0.5	0.2	-	-	0.2
5.3 Other specified soft tissue sarcoma	0.4	0.3	5.4	1.9	9.0	8.2
5.3.1 Specified soft tissue sarcoma	0.3	-	4.9	1.4	7.3	6.3
5.3.1.1 Specified (excluding Kaposi sarcoma)	0.3	-	1.1	1.3	4.3	6.0
5.3.1.2 Kaposi sarcoma	-	-	3.8	-	2.9	0.3
5.3.2 Unspecified soft tissue sarcoma	-	-	0.5	0.4	1.7	1.9
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	-	0.5	2.5	0.9	1.1	0.3
6.1 Germ cell and trophoblastic neoplasms of gonads	-	-	2.2	0.5	1.0	-
6.2 Germ cell and trophoblastic neoplasms of nongonadal sites	-	0.3	0.3	0.4	-	0.2
6.2.1 Intracranial sites	-	-	-	-	-	-
6.2.2 Other nongonadal sites	-	-	-	0.4	-	0.2

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table XXXII-3 - continued

AGE-ADJUSTED SEER INCIDENCE<sup>a</sup>, BY AGE GROUP AND SEX  
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>  
Black, 2001-2005

Site	Ages 0-14		Ages 15-39		Ages 40+	
	Male	Female	Male	Female	Male	Female
7. MELANOMA AND SKIN CARCINOMAS	-	-	0.5	0.6	4.1	3.0
7.1 Melanoma	-	-	0.3	0.5	2.8	2.1
7.2 Skin carcinomas	-	-	-	-	1.3	0.8
8. CARCINOMAS (excluding skin)	0.5	0.4	14.4	48.6	1292.0	739.0
8.1 Thyroid carcinoma	-	-	1.0	5.9	5.2	13.5
8.2 Other carcinoma of head and neck	-	-	1.8	1.5	64.8	17.4
8.2.1 Nasopharyngeal carcinoma	-	-	0.5	0.2	2.2	0.6
8.2.2 Other sites in lip, oral cavity and pharynx	-	-	1.0	1.1	35.5	11.4
8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck	-	-	0.3	-	27.1	5.3
8.3 Carcinoma of trachea, bronchus, and lung	-	-	1.1	1.3	233.2	118.3
8.4 Carcinoma of breast	-	-	-	22.8	3.5	249.4
8.5 Carcinoma of genitourinary tract	-	-	3.1	9.9	661.1	101.1
8.5.1 Carcinoma of kidney	-	-	1.9	1.3	44.6	20.2
8.5.2 Carcinoma of bladder	-	-	0.6	0.2	46.3	17.4
8.5.3 Carcinoma of gonads	-	-	-	-	-	-
8.5.4 Carcinoma of cervix and uterus	-	-	-	7.8	-	54.6
8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract	-	-	0.6	0.6	570.1	8.9
8.6 Carcinoma of gastrointestinal tract	-	-	6.4	4.9	298.1	199.7
8.6.1 Carcinoma of colon and rectum	-	-	4.0	3.3	162.3	124.5
8.6.2 Carcinoma of stomach	-	-	0.7	0.6	36.6	17.9
8.6.3 Carcinoma of liver and intrahepatic bile ducts	-	-	0.8	0.3	28.5	8.1
8.6.4 Carcinoma of pancreas	-	-	0.5	0.3	33.1	29.1
8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract	-	-	0.4	0.5	37.6	20.0
8.7 Carcinoma of other and ill-defined sites, NOS	-	-	0.8	2.3	26.0	39.6
8.7.1 Adrenocortical carcinoma	-	-	-	-	-	-
8.7.2 Carcinoma of other and ill-defined sites, NOS	-	-	0.8	2.3	25.8	39.5
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	2.6	2.3	1.3	1.9	40.7	35.2
9.1 Other pediatric and embryonal tumors, NOS	2.4	2.2	-	-	-	-
9.1.1 Wilms tumor	0.7	0.7	-	-	-	-
9.1.2 Neuroblastoma	0.9	0.8	-	-	-	-
9.1.3 Other pediatric and embryonal tumors, NOS	0.8	0.7	-	-	-	-
9.2 Other specified neoplasms, NOS	-	-	1.2	1.8	40.5	35.1
9.2.1 Paraganglioma and glomus tumors	-	-	-	-	-	-
9.2.2 Other specified gonadal tumors	-	-	-	0.3	-	0.6
9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS	-	-	0.7	0.7	33.7	22.7
9.2.4 Other specified neoplasms, NOS <sup>c</sup>	-	-	0.3	0.8	6.6	11.6
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	0.4	0.6	48.4	28.5

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

<sup>c</sup> Myeloproliferative disorders and myelodysplastic syndromes were first reported effective January 1, 2001 with the implementation of ICD-O 3.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table XXXII-4

AGE-ADJUSTED SEER INCIDENCE<sup>a</sup>, BY AGE GROUP AND SEX  
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>  
All Races, 2001-2005

Site	Ages 15-19		Ages 20-24		Ages 25-29		Ages 30-34		Ages 35-39	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
All Sites Combined	22.7	19.7	32.3	35.4	45.1	61.1	60.8	102.9	88.1	163.4
1. LEUKEMIAS	3.8	2.1	2.9	1.8	2.7	2.0	3.3	2.6	4.2	2.9
1.1 Acute lymphoid leukemia	2.4	0.9	1.3	0.5	0.8	0.5	0.8	0.6	0.9	0.5
1.2 Acute myeloid leukemia	1.1	0.9	1.0	0.9	1.0	1.0	1.3	1.3	1.5	1.3
1.3 Chronic myeloid leukemia	0.2	0.2	0.4	0.2	0.6	0.4	0.7	0.5	1.1	0.6
1.4 Other and unspecified leukemias	0.2	0.1	0.2	0.2	0.3	0.1	0.5	0.2	0.8	0.5
2. LYMPHOMAS	5.1	4.3	6.9	6.3	8.1	7.3	9.4	7.6	12.6	8.3
2.1 Non-Hodgkin Lymphoma	2.3	1.3	2.9	1.9	4.0	2.9	5.6	3.8	9.0	5.5
2.2 Hodgkin Lymphoma	2.8	3.1	4.0	4.5	4.1	4.4	3.8	3.8	3.5	2.8
3. CNS, INTRACRANIAL, INTRASPINAL	2.3	1.9	2.3	2.0	3.0	2.7	3.6	2.8	4.0	3.4
3.1 Astrocytoma	1.3	0.9	1.3	1.1	1.4	1.3	1.8	1.3	2.3	1.7
3.1.1 Specified low-grade astrocytic tumors	0.7	0.6	0.4	0.5	0.3	0.4	0.4	0.2	0.3	0.3
3.1.2 Glioblastoma and anaplastic astrocytoma	0.4	0.2	0.5	0.4	0.7	0.5	1.1	0.7	1.5	1.1
3.1.3 Astrocytoma, NOS	0.2	0.2	0.4	0.3	0.5	0.4	0.3	0.4	0.5	0.4
3.2 Other glioma	0.4	0.4	0.5	0.5	1.0	0.8	1.2	1.0	1.2	1.1
3.3 Ependymoma	0.2	0.2	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2
3.4 Medulloblastoma and other PNET	0.4	0.3	0.3	0.2	0.3	0.2	0.2	0.2	0.1	0.1
3.4.1 Medulloblastoma	0.2	0.1	0.2	-	0.1	-	0.1	0.1	-	-
3.4.2 Supratentorial PNET	0.2	0.2	0.1	-	0.2	-	-	-	-	-
3.5 Other specified intracranial and intraspinal neoplasms	-	-	-	-	-	-	-	-	-	0.1
3.6 Unspecified intracranial and intraspinal neoplasms	-	-	-	-	-	-	-	-	-	-
4. OSSEOUS & CHONDROMATOUS NEOPLASMS	2.1	1.3	1.2	0.9	0.7	0.7	0.6	0.6	0.8	0.6
4.1 Osteosarcoma	1.2	0.6	0.5	0.4	0.2	0.2	0.2	0.2	0.3	-
4.2 Chondrosarcoma	0.1	-	0.2	0.1	0.2	0.2	0.3	0.2	0.3	0.3
4.3 Ewing tumor	0.7	0.5	0.4	0.3	0.2	0.2	0.1	-	0.1	0.1
4.4 Other specified and unspecified bone tumors	0.1	-	-	-	-	-	-	-	0.2	-
5. SOFT TISSUE SARCOMAS	1.5	1.4	2.0	1.6	3.2	2.0	4.5	2.6	6.2	3.4
5.1 Fibromatous neoplasms	0.3	0.4	0.4	0.6	0.8	0.8	0.9	1.0	1.1	1.0
5.2 Rhabdomyosarcoma	0.5	0.3	0.3	-	-	-	-	-	-	-
5.3 Other specified soft tissue sarcoma	0.8	0.7	1.3	1.0	2.3	1.1	3.5	1.5	5.0	2.3
5.3.1 Specified soft tissue sarcoma	0.6	0.6	1.1	0.8	2.0	0.9	3.1	1.2	4.7	2.0
5.3.1.1 Specified (excluding Kaposi sarcoma)	0.6	0.6	0.8	0.8	1.0	0.9	1.2	1.2	1.6	2.0
5.3.1.2 Kaposi sarcoma	-	-	0.2	-	1.0	-	2.0	-	3.1	-
5.3.2 Unspecified soft tissue sarcoma	0.2	0.1	0.2	0.2	0.2	0.2	0.4	0.3	0.3	0.3
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	4.2	1.4	9.8	1.2	12.8	1.1	13.3	0.9	11.4	0.5
6.1 Germ cell and trophoblastic neoplasms of gonads	3.4	1.2	9.2	0.8	12.3	0.7	12.8	0.5	11.0	0.2
6.2 Germ cell and trophoblastic neoplasms of nongonadal sites	0.7	0.3	0.6	0.4	0.5	0.4	0.4	0.4	0.4	0.3
6.2.1 Intracranial sites	0.5	0.1	0.2	-	0.1	-	-	-	-	-
6.2.2 Other nongonadal sites	0.3	0.1	0.4	0.3	0.4	0.4	0.4	0.4	0.4	0.3

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.



Table XXXII-4 - continued

AGE-ADJUSTED SEER INCIDENCE<sup>a</sup>, BY AGE GROUP AND SEX  
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>  
All Races, 2001-2005

Site	Ages 15-19		Ages 20-24		Ages 25-29		Ages 30-34		Ages 35-39	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
7. MELANOMA AND SKIN CARCINOMAS	1.5	2.2	2.7	6.1	5.0	9.8	7.6	12.7	11.1	15.2
7.1 Melanoma	1.4	2.2	2.7	6.0	4.9	9.7	7.4	12.6	10.8	15.0
7.2 Skin carcinomas	-	-	-	-	-	-	0.2	0.1	0.2	0.2
8. CARCINOMAS (excluding skin)	2.0	4.7	4.0	14.8	8.9	34.5	17.2	71.3	35.7	125.8
8.1 Thyroid carcinoma	0.6	3.0	1.2	7.9	2.2	13.0	3.3	16.8	5.0	20.1
8.2 Other carcinoma of head and neck	0.5	0.4	0.6	0.8	1.1	1.1	2.1	1.8	4.0	2.6
8.2.1 Nasopharyngeal carcinoma	0.2	-	0.2	-	0.2	0.1	0.3	0.2	0.6	0.3
8.2.2 Other sites in lip, oral cavity and pharynx	0.2	0.3	0.3	0.6	0.8	0.9	1.4	1.4	2.8	1.8
8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck	-	-	-	-	0.1	-	0.4	0.2	0.6	0.4
8.3 Carcinoma of trachea, bronchus, and lung	-	-	0.3	0.3	0.5	0.5	1.0	1.1	3.2	3.8
8.4 Carcinoma of breast	-	-	-	1.2	-	7.5	-	25.7	0.1	58.3
8.5 Carcinoma of genitourinary tract	0.2	0.3	0.5	2.2	1.4	7.9	3.2	16.7	7.5	24.1
8.5.1 Carcinoma of kidney	-	0.2	0.2	0.3	0.8	0.7	1.7	1.4	4.1	2.5
8.5.2 Carcinoma of bladder	-	-	0.3	0.2	0.5	0.3	1.2	0.5	2.2	0.9
8.5.3 Carcinoma of gonads	-	-	-	-	-	-	-	-	-	-
8.5.4 Carcinoma of cervix and uterus	-	-	-	1.7	-	6.8	-	14.3	-	19.4
8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract	-	-	-	-	-	0.2	0.3	0.5	1.1	1.3
8.6 Carcinoma of gastrointestinal tract	0.5	0.4	1.2	1.4	3.2	2.7	6.8	6.0	14.6	11.3
8.6.1 Carcinoma of colon and rectum	0.3	0.3	0.7	0.9	2.0	1.8	4.2	4.0	9.2	7.7
8.6.2 Carcinoma of stomach	-	-	0.1	0.1	0.5	0.3	1.0	0.9	1.7	1.5
8.6.3 Carcinoma of liver and intrahepatic bile ducts	0.1	-	0.2	0.2	0.3	0.2	0.6	0.2	1.2	0.5
8.6.4 Carcinoma of pancreas	-	-	-	-	0.2	0.2	0.4	0.4	1.1	0.9
8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract	-	-	-	0.1	0.3	0.3	0.6	0.4	1.3	0.8
8.7 Carcinoma of other and ill-defined sites, NOS	-	0.4	0.2	1.0	0.4	1.7	0.7	3.1	1.3	5.7
8.7.1 Adrenocortical carcinoma	-	-	-	-	-	-	-	-	-	0.1
8.7.2 Carcinoma of other and ill-defined sites, NOS	-	0.3	0.2	1.0	0.4	1.7	0.7	3.0	1.2	5.6
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	0.3	0.4	0.3	0.5	0.4	0.8	0.9	1.2	1.6	2.3
9.1 Other pediatric and embryonal tumors, NOS	0.2	-	-	-	-	-	-	-	-	-
9.1.1 Wilms tumor	-	-	-	-	-	-	-	-	-	-
9.1.2 Neuroblastoma	-	-	-	-	-	-	-	-	-	-
9.1.3 Other pediatric and embryonal tumors, NOS	-	-	-	-	-	-	-	-	-	-
9.2 Other specified neoplasms, NOS	-	0.3	0.3	0.5	0.3	0.7	0.8	1.2	1.5	2.2
9.2.1 Paraganglioma and glomus tumors	-	-	-	-	-	-	-	-	-	-
9.2.2 Other specified gonadal tumors	-	-	-	-	-	0.2	-	0.2	-	0.2
9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS	-	-	-	-	-	-	0.5	0.2	0.9	0.7
9.2.4 Other specified neoplasms, NOS <sup>c</sup>	-	0.2	-	0.3	0.1	0.5	0.2	0.7	0.5	1.2
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	0.2	0.2	0.3	0.2	0.3	0.5	0.5	0.8

<sup>a</sup> Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>b</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>c</sup> Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

<sup>d</sup> Myeloproliferative disorders and myelodysplastic syndromes were first reported effective January 1, 2001 with the implementation of ICD-O 3.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table XXXII-5  
 AGE-ADJUSTED SEER INCIDENCE<sup>a</sup>, BY AGE GROUP AND SEX  
 By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>  
 White, 2001-2005

Site	Ages 15-19		Ages 20-24		Ages 25-29		Ages 30-34		Ages 35-39	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
All Sites Combined	24.7	21.2	35.5	37.9	48.7	65.6	64.9	108.2	91.3	168.2
1. LEUKEMIAS	4.3	2.2	3.0	1.9	2.8	2.1	3.4	2.6	4.3	3.0
1.1 Acute lymphoid leukemia	2.8	1.0	1.4	0.5	0.9	0.6	0.9	0.6	0.9	0.5
1.2 Acute myeloid leukemia	1.1	0.9	1.1	1.0	1.0	1.1	1.3	1.3	1.4	1.4
1.3 Chronic myeloid leukemia	0.2	-	0.4	0.2	0.5	0.4	0.7	0.4	1.1	0.6
1.4 Other and unspecified leukemias	0.2	-	-	0.2	0.3	-	0.5	0.3	0.9	0.5
2. LYMPHOMAS	5.4	4.6	7.3	6.7	8.4	7.7	9.7	8.0	12.6	8.5
2.1 Non-Hodgkin Lymphoma	2.4	1.2	2.8	1.7	3.9	2.9	5.7	3.7	8.8	5.4
2.2 Hodgkin Lymphoma	3.1	3.4	4.4	4.9	4.5	4.8	4.1	4.3	3.8	3.0
3. CNS, INTRACRANIAL, INTRASPINAL	2.5	2.0	2.5	2.3	3.3	3.0	4.1	3.0	4.5	4.0
3.1 Astrocytoma	1.4	1.0	1.4	1.3	1.6	1.5	2.1	1.5	2.6	2.0
3.1.1 Specified low-grade astrocytic tumors	0.8	0.7	0.4	0.5	0.3	0.4	0.4	0.3	0.4	0.3
3.1.2 Glioblastoma and anaplastic astrocytoma	0.4	0.2	0.5	0.5	0.7	0.6	1.3	0.7	1.7	1.3
3.1.3 Astrocytoma, NOS	0.2	0.2	0.4	0.3	0.5	0.4	0.4	0.5	0.6	0.4
3.2 Other glioma	0.4	0.4	0.6	0.6	1.1	1.0	1.4	1.0	1.4	1.4
3.3 Ependymoma	0.2	0.2	-	-	0.2	0.2	0.1	0.3	0.2	0.3
3.4 Medulloblastoma and other PNET	0.5	0.4	0.3	0.2	0.3	0.3	0.3	0.2	-	-
3.4.1 Medulloblastoma	0.2	-	0.2	-	-	-	0.2	-	-	-
3.4.2 Supratentorial PNET	0.3	0.2	0.2	-	-	-	-	-	-	-
3.5 Other specified intracranial and intraspinal neoplasms	-	-	-	-	-	-	-	-	-	-
3.6 Unspecified intracranial and intraspinal neoplasms	-	-	-	-	-	-	-	-	-	-
4. OSSEOUS & CHONDROMATOUS NEOPLASMS	2.2	1.4	1.3	1.0	0.7	0.8	0.6	0.7	0.9	0.7
4.1 Osteosarcoma	1.1	0.6	0.6	0.4	0.2	0.3	0.2	0.2	0.2	-
4.2 Chondrosarcoma	0.2	-	0.2	-	0.2	0.2	0.3	0.3	0.3	0.3
4.3 Ewing tumor	0.8	0.6	0.4	0.3	0.2	0.2	-	-	-	0.2
4.4 Other specified and unspecified bone tumors	-	-	-	-	-	-	-	-	0.2	-
5. SOFT TISSUE SARCOMAS	1.5	1.4	1.9	1.5	2.9	1.9	4.0	2.5	5.6	3.1
5.1 Fibromatous neoplasms	0.3	0.3	0.4	0.5	0.8	0.7	0.8	0.9	1.0	0.9
5.2 Rhabdomyosarcoma	0.5	0.3	0.3	-	-	-	-	-	-	-
5.3 Other specified soft tissue sarcoma	0.7	0.7	1.2	0.9	2.0	1.1	3.1	1.5	4.5	2.2
5.3.1 Specified soft tissue sarcoma	0.6	0.6	1.0	0.8	1.8	0.9	2.7	1.2	4.2	2.0
5.3.1.1 Specified (excluding Kaposi sarcoma)	0.6	0.6	0.9	0.8	1.1	0.9	1.2	1.2	1.7	1.9
5.3.1.2 Kaposi sarcoma	-	-	-	-	0.7	-	1.5	-	2.5	-
5.3.2 Unspecified soft tissue sarcoma	0.2	-	0.2	-	0.2	0.2	0.3	0.3	0.3	0.3
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	4.8	1.4	11.7	1.1	15.2	1.1	15.9	0.9	13.5	0.4
6.1 Germ cell and trophoblastic neoplasms of gonads	4.1	1.2	11.1	0.8	14.8	0.7	15.4	0.5	13.0	0.2
6.2 Germ cell and trophoblastic neoplasms of nongonadal sites	0.6	0.2	0.7	0.3	0.5	0.4	0.5	0.4	0.4	0.2
6.2.1 Intracranial sites	0.4	-	0.2	-	-	-	-	-	-	-
6.2.2 Other nongonadal sites	0.2	-	0.5	0.2	0.4	0.4	0.5	0.4	0.4	0.2

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1977; 40:1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table XXXII-5 - continued

AGE-ADJUSTED SEER INCIDENCE<sup>a</sup>, BY AGE GROUP AND SEX  
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>  
White, 2001-2005

Site	Ages 15-19		Ages 20-24		Ages 25-29		Ages 30-34		Ages 35-39	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
7. MELANOMA AND SKIN CARCINOMAS	1.8	2.7	3.3	7.3	6.0	12.2	9.0	15.5	13.2	18.5
7.1 Melanoma	1.8	2.7	3.3	7.3	5.9	12.1	8.8	15.4	12.9	18.4
7.2 Skin carcinomas	-	-	-	-	-	-	0.2	-	0.2	0.2
8. CARCINOMAS (excluding skin)	2.0	5.0	4.0	15.3	8.8	35.8	17.0	73.3	34.9	127.2
8.1 Thyroid carcinoma	0.7	3.3	1.2	8.7	2.4	14.2	3.5	18.5	5.5	21.5
8.2 Other carcinoma of head and neck	0.4	0.3	0.6	0.8	1.0	1.0	2.0	1.7	3.8	2.3
8.2.1 Nasopharyngeal carcinoma	-	-	-	-	-	-	-	-	0.2	-
8.2.2 Other sites in lip, oral cavity and pharynx	0.3	0.3	0.4	0.6	0.7	0.8	1.5	1.3	2.9	1.8
8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck	-	-	-	-	-	-	0.4	0.3	0.7	0.4
8.3 Carcinoma of trachea, bronchus, and lung	-	-	0.3	0.3	0.5	0.6	0.9	1.1	3.1	3.8
8.4 Carcinoma of breast	-	-	-	1.1	-	7.4	-	25.5	-	57.9
8.5 Carcinoma of genitourinary tract	0.2	0.4	0.5	2.1	1.5	8.3	3.4	17.7	7.7	25.2
8.5.1 Carcinoma of kidney	-	0.2	0.2	0.3	0.8	0.7	1.8	1.5	4.2	2.6
8.5.2 Carcinoma of bladder	-	-	0.3	0.2	0.5	0.4	1.3	0.5	2.4	1.0
8.5.3 Carcinoma of gonads	-	-	-	-	-	-	-	-	-	-
8.5.4 Carcinoma of cervix and uterus	-	-	-	1.6	-	7.2	-	15.1	-	20.2
8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract	-	-	-	-	-	-	0.2	0.5	1.0	1.3
8.6 Carcinoma of gastrointestinal tract	0.5	0.5	1.3	1.4	3.1	2.7	6.4	5.7	13.5	10.8
8.6.1 Carcinoma of colon and rectum	0.2	0.3	0.8	0.9	2.0	1.8	4.2	3.9	8.9	7.4
8.6.2 Carcinoma of stomach	-	-	-	-	0.5	0.3	0.9	0.7	1.6	1.3
8.6.3 Carcinoma of liver and intrahepatic bile ducts	-	-	0.2	0.2	-	-	0.4	0.2	0.6	0.4
8.6.4 Carcinoma of pancreas	-	-	-	-	0.2	0.2	0.3	0.5	1.0	0.9
8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract	-	-	-	-	0.3	0.3	0.6	0.4	1.4	0.7
8.7 Carcinoma of other and ill-defined sites, NOS	-	0.4	0.2	1.0	0.3	1.6	0.7	3.1	1.2	5.7
8.7.1 Adrenocortical carcinoma	-	-	-	-	-	-	-	-	-	-
8.7.2 Carcinoma of other and ill-defined sites, NOS	-	0.4	-	0.9	0.3	1.6	0.7	3.0	1.2	5.6
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	0.2	0.4	0.3	0.5	0.3	0.8	0.9	1.2	1.4	2.0
9.1 Other pediatric and embryonal tumors, NOS	0.2	-	-	-	-	-	-	-	-	-
9.1.1 Wilms tumor	-	-	-	-	-	-	-	-	-	-
9.1.2 Neuroblastoma	-	-	-	-	-	-	-	-	-	-
9.1.3 Other pediatric and embryonal tumors, NOS	-	-	-	-	-	-	-	-	-	-
9.2 Other specified neoplasms, NOS	-	0.3	0.2	0.4	0.2	0.7	0.8	1.1	1.3	2.0
9.2.1 Paraganglioma and glomus tumors	-	-	-	-	-	-	-	-	-	-
9.2.2 Other specified gonadal tumors	-	-	-	-	-	-	-	0.2	-	0.2
9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS	-	-	-	-	-	-	0.5	0.2	0.8	0.6
9.2.4 Other specified neoplasms, NOS <sup>c</sup>	-	0.2	-	0.3	-	0.5	0.2	0.7	0.5	1.2
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	0.2	0.2	0.3	0.2	0.3	0.5	0.5	0.8

<sup>a</sup> Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>b</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>c</sup> Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

<sup>d</sup> Myeloproliferative disorders and myelodysplastic syndromes were first reported effective January 1, 2001 with the implementation of ICD-O 3.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table XXXII-6  
 AGE-ADJUSTED SEER INCIDENCE<sup>a</sup>, BY AGE GROUP AND SEX  
 By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>  
 Black, 2001-2005

Site	Ages 15-19		Ages 20-24		Ages 25-29		Ages 30-34		Ages 35-39	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
All Sites Combined	14.1	13.1	19.2	25.2	32.4	45.8	47.9	87.5	83.6	148.0
1. LEUKEMIAS	2.0	1.8	2.5	1.5	2.9	1.6	3.4	2.6	4.2	2.5
1.1 Acute lymphoid leukemia	-	-	1.1	-	-	-	-	-	-	-
1.2 Acute myeloid leukemia	0.9	-	-	-	-	-	1.7	1.1	1.8	1.2
1.3 Chronic myeloid leukemia	-	-	-	-	-	-	-	-	1.4	-
1.4 Other and unspecified leukemias	-	-	-	-	-	-	-	-	-	-
2. LYMPHOMAS	4.1	3.6	5.5	6.0	9.7	7.0	10.7	8.4	17.0	10.2
2.1 Non-Hodgkin Lymphoma	2.4	1.4	2.9	2.7	5.8	2.9	7.2	4.9	13.4	7.6
2.2 Hodgkin Lymphoma	1.7	2.2	2.5	3.4	3.9	4.1	3.5	3.5	3.7	2.6
3. CNS, INTRACRANIAL, INTRASPINAL	1.5	1.1	1.4	1.0	1.4	1.4	1.7	1.9	2.5	1.7
3.1 Astrocytoma	0.9	-	1.0	-	-	-	-	0.9	1.4	-
3.1.1 Specified low-grade astrocytic tumors	-	-	-	-	-	-	-	-	-	-
3.1.2 Glioblastoma and anaplastic astrocytoma	-	-	-	-	-	-	-	-	-	-
3.1.3 Astrocytoma, NOS	-	-	-	-	-	-	-	-	-	-
3.2 Other glioma	-	-	-	-	-	-	-	-	-	-
3.3 Ependymoma	-	-	-	-	-	-	-	-	-	-
3.4 Medulloblastoma and other PNET	-	-	-	-	-	-	-	-	-	-
3.4.1 Medulloblastoma	-	-	-	-	-	-	-	-	-	-
3.4.2 Supratentorial PNET	-	-	-	-	-	-	-	-	-	-
3.5 Other specified intracranial and intraspinal neoplasms	-	-	-	-	-	-	-	-	-	-
3.6 Unspecified intracranial and intraspinal neoplasms	-	-	-	-	-	-	-	-	-	-
4. OSSEOUS & CHONDROMATOUS NEOPLASMS	1.6	-	-	-	-	-	-	-	-	-
4.1 Osteosarcoma	1.5	-	-	-	-	-	-	-	-	-
4.2 Chondrosarcoma	-	-	-	-	-	-	-	-	-	-
4.3 Ewing tumor	-	-	-	-	-	-	-	-	-	-
4.4 Other specified and unspecified bone tumors	-	-	-	-	-	-	-	-	-	-
5. SOFT TISSUE SARCOMAS	1.6	1.8	2.9	3.0	5.8	3.0	9.3	3.5	12.2	4.8
5.1 Fibromatous neoplasms	-	-	-	1.0	1.2	1.5	1.7	1.5	1.5	1.4
5.2 Rhabdomyosarcoma	-	-	-	-	-	-	-	-	-	-
5.3 Other specified soft tissue sarcoma	1.0	-	2.3	1.8	4.7	1.5	7.3	1.9	10.6	3.2
5.3.1 Specified soft tissue sarcoma	-	-	1.9	1.3	4.4	1.0	6.8	1.5	9.8	2.6
5.3.1.1 Specified (excluding Kaposi sarcoma)	-	-	-	1.3	-	-	1.2	1.5	1.8	2.2
5.3.1.2 Kaposi sarcoma	-	-	1.1	-	3.4	-	5.6	-	8.1	-
5.3.2 Unspecified soft tissue sarcoma	-	-	-	-	-	-	-	-	-	-
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	1.1	1.2	1.9	-	2.9	-	3.6	0.9	3.0	-
6.1 Germ cell and trophoblastic neoplasms of gonads	-	-	1.7	-	2.3	-	3.3	-	2.9	-
6.2 Germ cell and trophoblastic neoplasms of nongonadal sites	-	-	-	-	-	-	-	-	-	-
6.2.1 Intracranial sites	-	-	-	-	-	-	-	-	-	-
6.2.2 Other nongonadal sites	-	-	-	-	-	-	-	-	-	-

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table XXXIII-6 - continued

AGE-ADJUSTED SEER INCIDENCE<sup>a</sup>, BY AGE GROUP AND SEX  
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>  
Black, 2001-2005

Site	Ages 15-19		Ages 20-24		Ages 25-29		Ages 30-34		Ages 35-39	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
7. MELANOMA AND SKIN CARCINOMAS	-	-	-	-	-	-	-	-	1.2	-
7.1 Melanoma	-	-	-	-	-	-	-	-	-	-
7.2 Skin carcinomas	-	-	-	-	-	-	-	-	-	-
8. CARCINOMAS (excluding skin)	1.9	2.2	3.4	11.1	7.8	29.7	15.8	66.1	38.7	120.6
8.1 Thyroid carcinoma	-	-	-	3.2	1.1	6.2	1.4	7.7	2.0	11.0
8.2 Other carcinoma of head and neck	-	-	-	-	1.2	1.3	2.0	1.6	4.0	3.0
8.2.1 Nasopharyngeal carcinoma	-	-	-	-	-	-	-	-	-	-
8.2.2 Other sites in lip, oral cavity and pharynx	-	-	-	-	-	1.1	1.0	1.2	2.5	2.1
8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck	-	-	-	-	-	-	-	-	-	-
8.3 Carcinoma of trachea, bronchus, and lung	-	-	-	-	-	-	1.2	0.9	3.3	4.2
8.4 Carcinoma of breast	-	-	-	1.8	-	9.8	-	30.9	-	63.6
8.5 Carcinoma of genitourinary tract	-	-	-	2.8	1.3	8.4	3.2	15.2	9.2	20.7
8.5.1 Carcinoma of kidney	-	-	-	-	-	1.1	2.0	1.8	5.2	2.8
8.5.2 Carcinoma of bladder	-	-	-	-	-	-	-	-	1.8	-
8.5.3 Carcinoma of gonads	-	-	-	-	-	-	-	-	-	-
8.5.4 Carcinoma of cervix and uterus	-	-	-	2.2	-	6.8	-	12.4	-	15.9
8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract	-	-	-	-	-	-	-	-	2.1	1.5
8.6 Carcinoma of gastrointestinal tract	-	-	1.1	1.6	2.7	2.2	7.2	6.6	18.4	12.6
8.6.1 Carcinoma of colon and rectum	-	-	-	1.1	1.5	1.5	4.5	4.6	11.9	8.2
8.6.2 Carcinoma of stomach	-	-	-	-	-	-	-	-	1.8	1.4
8.6.3 Carcinoma of liver and intrahepatic bile ducts	-	-	-	-	-	-	1.1	-	1.8	-
8.6.4 Carcinoma of pancreas	-	-	-	-	-	-	-	-	1.6	-
8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract	-	-	-	-	-	-	-	-	1.3	1.5
8.7 Carcinoma of other and ill-defined sites, NOS	-	-	-	-	-	1.5	-	3.2	1.6	5.4
8.7.1 Adrenocortical carcinoma	-	-	-	-	-	-	-	-	-	-
8.7.2 Carcinoma of other and ill-defined sites, NOS	-	-	-	-	-	1.5	-	3.2	1.6	5.3
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	-	-	-	-	-	-	1.4	2.1	3.3	4.9
9.1 Other pediatric and embryonal tumors, NOS	-	-	-	-	-	-	-	-	-	-
9.1.1 Wilms tumor	-	-	-	-	-	-	-	-	-	-
9.1.2 Neuroblastoma	-	-	-	-	-	-	-	-	-	-
9.1.3 Other pediatric and embryonal tumors, NOS	-	-	-	-	-	-	-	-	-	-
9.2 Other specified neoplasms, NOS	-	-	-	-	-	-	1.2	2.1	3.2	4.6
9.2.1 Paraganglioma and glomus tumors	-	-	-	-	-	-	-	-	-	-
9.2.2 Other specified gonadal tumors	-	-	-	-	-	-	-	-	-	-
9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS	-	-	-	-	-	-	-	-	2.2	2.1
9.2.4 Other specified neoplasms, NOS <sup>c</sup>	-	-	-	-	-	-	-	1.1	-	1.9
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	-	-	-	-	-	-	-	1.4

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

<sup>c</sup> Myeloproliferative disorders and myelodysplastic syndromes were first reported effective January 1, 2001 with the implementation of ICD-O 3.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table XXXII-7

AGE-ADJUSTED SEER INCIDENCE<sup>a</sup>, BY YEAR AND SEX  
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>  
All Races, Ages 15-19

Both Sexes	1976-2005			1996-2005		
	No.	Rate	AAPC <sup>c</sup>	No.	Rate	AAPC <sup>c</sup>
All Sites Combined	10,847	20.1	0.5*	3,885	20.9	0.5*
1. Leukemias	1,288	2.4	1.0*	483	2.6	1.0*
2. Lymphomas	2,712	5.0	-0.2	899	4.8	-0.2
3. CNS, intracranial, intraspinal	1,070	2.0	0.4	379	2.0	0.4
4. Osseous & chondromatous neoplasms	845	1.6	0.6	302	1.6	0.6
5. Soft tissue sarcomas	817	1.5	0.4	303	1.6	0.4
6. Germ cell and trophoblastic neoplasms	1,320	2.4	1.0*	485	2.6	1.0*
7. Melanoma and skin carcinomas	826	1.5	1.3*	322	1.7	1.3*
8. Carcinomas (excluding skin)	1,753	3.2	0.7*	651	3.5	0.7*
9. Miscellaneous specified neoplasms, NOS	167	0.3	-0.2	51	0.3	-0.2
10. Unspecified malignant neoplasms	49	0.1	-	-	-	-

  

Males	1976-2005			1996-2005		
	No.	Rate	AAPC <sup>c</sup>	No.	Rate	AAPC <sup>c</sup>
All Sites Combined	5,732	20.8	0.7*	2,099	22.0	0.7*
1. Leukemias	788	2.9	0.7	295	3.1	0.7
2. Lymphomas	1,445	5.2	0.0	491	5.1	0.0
3. CNS, intracranial, intraspinal	626	2.3	0.5	224	2.3	0.5
4. Osseous & chondromatous neoplasms	552	2.0	0.7	198	2.1	0.7
5. Soft tissue sarcomas	433	1.6	0.3	160	1.7	0.3
6. Germ cell and trophoblastic neoplasms	961	3.5	1.3*	369	3.9	1.3*
7. Melanoma and skin carcinomas	323	1.2	2.1*	138	1.4	2.1*
8. Carcinomas (excluding skin)	508	1.8	1.2*	200	2.1	1.2*
9. Miscellaneous specified neoplasms, NOS	76	0.3	-	22	0.2	-
10. Unspecified malignant neoplasms	20	0.1	-	-	-	-

  

Females	1976-2005			1996-2005		
	No.	Rate	AAPC <sup>c</sup>	No.	Rate	AAPC <sup>c</sup>
All Sites Combined	5,115	19.4	0.3*	1,786	19.7	0.3*
1. Leukemias	500	1.9	1.4*	188	2.1	1.4*
2. Lymphomas	1,267	4.8	-0.3	408	4.5	-0.3
3. CNS, intracranial, intraspinal	444	1.7	0.1	155	1.7	0.1
4. Osseous & chondromatous neoplasms	293	1.1	0.4	104	1.1	0.4
5. Soft tissue sarcomas	384	1.5	0.6	143	1.6	0.6
6. Germ cell and trophoblastic neoplasms	359	1.4	0.2	116	1.3	0.2
7. Melanoma and skin carcinomas	503	1.9	0.9	184	2.0	0.9
8. Carcinomas (excluding skin)	1,245	4.7	0.5	451	5.0	0.5
9. Miscellaneous specified neoplasms, NOS	91	0.3	-	29	0.3	-
10. Unspecified malignant neoplasms	29	0.1	-	-	-	-

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

<sup>b</sup> Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

<sup>c</sup> The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1976-2005.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

\* The AAPC is significantly different from zero (p<.05).

Table XXXII-8

AGE-ADJUSTED SEER INCIDENCE<sup>a</sup>, BY YEAR AND SEX  
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>  
All Races, Ages 20-24

Both Sexes	1976-2005			1996-2005		
	No.	Rate	AAPC <sup>c</sup>	No.	Rate	AAPC <sup>c</sup>
All Sites Combined	18,620	33.4	0.8*	6,503	36.0	0.8*
1. Leukemias	1,206	2.2	1.1*	433	2.4	1.1*
2. Lymphomas	3,961	7.1	0.9	1,308	7.3	-0.3
3. CNS, intracranial, intraspinal	1,233	2.2	0.9*	425	2.4	0.9*
4. Osseous & chondromatous neoplasms	484	0.9	1.7*	183	1.0	1.7*
5. Soft tissue sarcomas	1,186	2.1	1.5	379	2.1	-1.4
6. Germ cell and trophoblastic neoplasms	2,901	5.2	0.8*	1,026	5.7	0.8*
7. Melanoma and skin carcinomas	2,357	4.2	1.6*	909	5.0	1.6*
8. Carcinomas (excluding skin)	4,991	8.9	-0.1	1,726	9.6	1.2*
9. Miscellaneous specified neoplasms, NOS	185	0.3	1.6*	70	0.4	1.6*
10. Unspecified malignant neoplasms	116	0.2	1.4	44	0.2	1.4

  

Males	1976-2005			1996-2005		
	No.	Rate	AAPC <sup>c</sup>	No.	Rate	AAPC <sup>c</sup>
All Sites Combined	9,232	32.6	0.5*	3,135	33.9	0.5*
1. Leukemias	713	2.5	0.9*	254	2.7	0.9*
2. Lymphomas	2,119	7.5	0.4	698	7.6	0.4
3. CNS, intracranial, intraspinal	708	2.5	0.3	232	2.5	0.3
4. Osseous & chondromatous neoplasms	287	1.0	1.1	106	1.1	1.1
5. Soft tissue sarcomas	710	2.5	0.8	208	2.3	-3.8*
6. Germ cell and trophoblastic neoplasms	2,591	9.2	0.8*	926	10.0	0.8*
7. Melanoma and skin carcinomas	830	2.9	0.5	293	3.2	0.5
8. Carcinomas (excluding skin)	1,153	4.1	-0.2	377	4.1	-0.2
9. Miscellaneous specified neoplasms, NOS	75	0.3	-	26	0.3	-
10. Unspecified malignant neoplasms	46	0.2	-	-	-	-

  

Females	1976-2005			1996-2005		
	No.	Rate	AAPC <sup>c</sup>	No.	Rate	AAPC <sup>c</sup>
All Sites Combined	9,388	34.1	0.7	3,368	38.3	1.4*
1. Leukemias	493	1.8	0.0	179	2.0	-1.3
2. Lymphomas	1,842	6.7	1.7	610	6.9	3.9*
3. CNS, intracranial, intraspinal	525	1.9	2.0*	193	2.2	2.0*
4. Osseous & chondromatous neoplasms	197	0.7	2.0*	77	0.9	2.0*
5. Soft tissue sarcomas	476	1.7	1.2*	171	1.9	1.2*
6. Germ cell and trophoblastic neoplasms	310	1.1	-0.2	100	1.1	-0.2
7. Melanoma and skin carcinomas	1,527	5.5	2.1*	616	7.0	2.1*
8. Carcinomas (excluding skin)	3,838	13.9	0.2	1,349	15.3	1.4*
9. Miscellaneous specified neoplasms, NOS	110	0.4	2.0*	44	0.5	2.0*
10. Unspecified malignant neoplasms	70	0.3	-	29	0.3	-

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

<sup>b</sup> Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

<sup>c</sup> The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1976-2005.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

\* The AAPC is significantly different from zero (p<.05).

Table XXXII-9

AGE-ADJUSTED SEER INCIDENCE<sup>a</sup>, BY YEAR AND SEX  
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>  
All Races, Ages 25-29

Both Sexes	1976-2005			1996-2005		
	No.	Rate	AAPC <sup>c</sup>	No.	Rate	AAPC <sup>c</sup>
All Sites Combined	31,927	54.0	0.8*	10,710	56.5	0.9
1. Leukemias	1,342	2.3	0.6	470	2.5	0.6
2. Lymphomas	4,878	8.3	0.5	1,575	8.3	-2.3*
3. CNS, intracranial, intraspinal	1,685	2.8	1.3*	605	3.2	1.3*
4. Osseous & chondromatous neoplasms	373	0.6	0.8	130	0.7	0.8
5. Soft tissue sarcomas	2,624	4.4	2.3	570	3.0	-5.0*
6. Germ cell and trophoblastic neoplasms	4,049	6.8	1.5*	1,359	7.2	2.0
7. Melanoma and skin carcinomas	4,357	7.4	1.2*	1,602	8.4	1.2*
8. Carcinomas (excluding skin)	12,175	20.6	0.4	4,234	22.3	1.3*
9. Miscellaneous specified neoplasms, NOS	285	0.5	1.9*	118	0.6	1.9*
10. Unspecified malignant neoplasms	159	0.3	-	47	0.2	-
Males	1976-2005			1996-2005		
	No.	Rate	AAPC <sup>c</sup>	No.	Rate	AAPC <sup>c</sup>
All Sites Combined	14,597	49.1	1.0*	4,703	48.9	0.1
1. Leukemias	783	2.6	0.3	275	2.9	0.3
2. Lymphomas	2,804	9.4	0.1	857	8.9	-4.0*
3. CNS, intracranial, intraspinal	907	3.0	1.1*	319	3.3	1.1*
4. Osseous & chondromatous neoplasms	216	0.7	0.1	65	0.7	0.1
5. Soft tissue sarcomas	1,967	6.6	4.0*	375	3.9	-4.7*
6. Germ cell and trophoblastic neoplasms	3,722	12.5	1.6*	1,273	13.2	1.6
7. Melanoma and skin carcinomas	1,601	5.4	0.3	550	5.7	0.3
8. Carcinomas (excluding skin)	2,422	8.1	0.9	917	9.5	2.8*
9. Miscellaneous specified neoplasms, NOS	105	0.4	-	50	0.5	-
10. Unspecified malignant neoplasms	70	0.2	-	22	0.2	-
Females	1976-2005			1996-2005		
	No.	Rate	AAPC <sup>c</sup>	No.	Rate	AAPC <sup>c</sup>
All Sites Combined	17,330	59.0	0.8*	6,007	64.2	0.8*
1. Leukemias	559	1.9	0.9	195	2.1	0.9
2. Lymphomas	2,074	7.1	1.2*	718	7.7	1.2*
3. CNS, intracranial, intraspinal	778	2.6	1.5*	286	3.1	1.5*
4. Osseous & chondromatous neoplasms	157	0.5	1.3	65	0.7	1.3
5. Soft tissue sarcomas	657	2.2	-0.4	195	2.1	-6.1*
6. Germ cell and trophoblastic neoplasms	327	1.1	-1.2	86	0.9	-1.2
7. Melanoma and skin carcinomas	2,756	9.4	2.1*	1,052	11.2	4.3*
8. Carcinomas (excluding skin)	9,753	33.2	0.3	3,317	35.4	1.0*
9. Miscellaneous specified neoplasms, NOS	180	0.6	1.0	68	0.7	1.0
10. Unspecified malignant neoplasms	89	0.3	-	25	0.3	-

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

<sup>b</sup> Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

<sup>c</sup> The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1976-2005.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

\* The AAPC is significantly different from zero (p<.05).



Table XXXII-10

AGE-ADJUSTED SEER INCIDENCE<sup>a</sup>, BY YEAR AND SEX  
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>  
All Races, Ages 30-34

Both Sexes	1976-2005			1996-2005		
	No.	Rate	AAPC <sup>c</sup>	No.	Rate	AAPC <sup>c</sup>
All Sites Combined	50,147	83.5	0.8*	17,451	84.3	0.3
1. Leukemias	1,677	2.8	0.5	613	3.0	0.5
2. Lymphomas	5,570	9.3	1.3*	1,959	9.5	-3.3*
3. CNS, intracranial, intraspinal	2,008	3.3	0.3	701	3.4	0.3
4. Osseous & chondromatous neoplasms	377	0.6	1.3*	144	0.7	1.3*
5. Soft tissue sarcomas	4,581	7.6	2.6	960	4.6	-9.0*
6. Germ cell and trophoblastic neoplasms	4,138	6.9	1.7*	1,573	7.6	-0.2
7. Melanoma and skin carcinomas	6,396	10.6	1.0	2,318	11.2	1.9*
8. Carcinomas (excluding skin)	24,673	41.1	0.3	8,886	42.9	1.9*
9. Miscellaneous specified neoplasms, NOS	494	0.8	1.5*	209	1.0	1.5*
10. Unspecified malignant neoplasms	233	0.4	0.6	88	0.4	0.6

  

Males	1976-2005			1996-2005		
	No.	Rate	AAPC <sup>c</sup>	No.	Rate	AAPC <sup>c</sup>
All Sites Combined	21,278	70.8	1.2*	6,914	66.1	-1.5
1. Leukemias	967	3.2	0.7	363	3.5	0.7
2. Lymphomas	3,508	11.7	1.4	1,159	11.1	-4.8*
3. CNS, intracranial, intraspinal	1,175	3.9	0.1	408	3.9	0.1
4. Osseous & chondromatous neoplasms	209	0.7	0.9	79	0.8	0.9
5. Soft tissue sarcomas	3,789	12.6	4.0	698	6.7	-11.9*
6. Germ cell and trophoblastic neoplasms	3,871	12.9	1.8*	1,486	14.2	0.0
7. Melanoma and skin carcinomas	2,588	8.6	-0.2	865	8.3	-0.2
8. Carcinomas (excluding skin)	4,898	16.3	0.4	1,737	16.6	2.4*
9. Miscellaneous specified neoplasms, NOS	186	0.6	1.7	85	0.8	1.7
10. Unspecified malignant neoplasms	87	0.3	-	34	0.3	-

  

Females	1976-2005			1996-2005		
	No.	Rate	AAPC <sup>c</sup>	No.	Rate	AAPC <sup>c</sup>
All Sites Combined	28,869	96.2	0.6*	10,537	102.8	1.6*
1. Leukemias	710	2.4	0.2	250	2.4	0.2
2. Lymphomas	2,062	6.9	1.5*	800	7.8	1.5*
3. CNS, intracranial, intraspinal	833	2.8	0.5	293	2.9	0.5
4. Osseous & chondromatous neoplasms	168	0.6	-	65	0.6	-
5. Soft tissue sarcomas	792	2.6	-0.1	262	2.6	-0.1
6. Germ cell and trophoblastic neoplasms	267	0.9	-0.7	87	0.8	-0.7
7. Melanoma and skin carcinomas	3,808	12.7	1.2*	1,453	14.2	1.2*
8. Carcinomas (excluding skin)	19,775	65.9	0.4*	7,149	69.7	1.8*
9. Miscellaneous specified neoplasms, NOS	308	1.0	1.5*	124	1.2	1.5*
10. Unspecified malignant neoplasms	146	0.5	0.9	54	0.5	0.9

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

<sup>b</sup> Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

<sup>c</sup> The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1976-2005.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

\* The AAPC is significantly different from zero (p<.05).

Table XXXII-11

AGE-ADJUSTED SEER INCIDENCE<sup>a</sup>, BY YEAR AND SEX  
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>  
All Races, Ages 35-39

Both Sexes	1976-2005			1996-2005		
	No.	Rate	AAPC <sup>c</sup>	No.	Rate	AAPC <sup>c</sup>
All Sites Combined	73,400	130.5	0.5*	28,090	129.4	0.1
1. Leukemias	2,031	3.6	-0.3	784	3.6	-0.3
2. Lymphomas	6,299	11.2	1.9*	2,444	11.3	-1.9*
3. CNS, intracranial, intraspinal	2,227	4.0	-0.1	847	3.9	-0.1
4. Osseous & chondromatous neoplasms	349	0.6	1.3	141	0.6	1.3
5. Soft tissue sarcomas	5,296	9.4	2.7	1,261	5.8	-6.4
6. Germ cell and trophoblastic neoplasms	3,260	5.8	2.0*	1,416	6.5	0.6
7. Melanoma and skin carcinomas	7,943	14.1	1.6*	3,223	14.8	0.1
8. Carcinomas (excluding skin)	44,715	79.5	0.2	17,455	80.4	1.2*
9. Miscellaneous specified neoplasms, NOS	908	1.6	1.2*	389	1.8	1.2*
10. Unspecified malignant neoplasms	372	0.7	-0.2	130	0.6	-0.2

  

Males	1976-2005			1996-2005		
	No.	Rate	AAPC <sup>c</sup>	No.	Rate	AAPC <sup>c</sup>
All Sites Combined	28,258	100.8	0.5	10,275	94.3	-1.1
1. Leukemias	1,187	4.2	-0.2	451	4.1	-0.2
2. Lymphomas	4,185	14.9	2.0*	1,535	14.1	-3.5*
3. CNS, intracranial, intraspinal	1,292	4.6	-0.2	482	4.4	-0.2
4. Osseous & chondromatous neoplasms	200	0.7	0.0	73	0.7	0.0
5. Soft tissue sarcomas	4,279	15.3	5.2*	895	8.2	-8.0
6. Germ cell and trophoblastic neoplasms	3,096	11.0	2.1*	1,362	12.5	0.6
7. Melanoma and skin carcinomas	3,543	12.6	0.6	1,349	12.4	-1.1*
8. Carcinomas (excluding skin)	9,945	35.5	0.0	3,915	35.9	1.4*
9. Miscellaneous specified neoplasms, NOS	370	1.3	0.4	158	1.5	0.4
10. Unspecified malignant neoplasms	161	0.6	-0.3	55	0.5	-0.3

  

Females	1976-2005			1996-2005		
	No.	Rate	AAPC <sup>c</sup>	No.	Rate	AAPC <sup>c</sup>
All Sites Combined	45,142	160.1	0.5*	17,815	164.7	0.9*
1. Leukemias	844	3.0	0.0	333	3.1	-2.0
2. Lymphomas	2,114	7.5	1.6*	909	8.4	1.6*
3. CNS, intracranial, intraspinal	935	3.3	-0.1	365	3.4	-0.1
4. Osseous & chondromatous neoplasms	149	0.5	-	68	0.6	-
5. Soft tissue sarcomas	1,017	3.6	-1.2*	366	3.4	-1.2*
6. Germ cell and trophoblastic neoplasms	164	0.6	-0.5	54	0.5	-0.5
7. Melanoma and skin carcinomas	4,400	15.6	1.9	1,874	17.3	-0.1
8. Carcinomas (excluding skin)	34,770	123.3	0.3	13,540	125.1	1.1*
9. Miscellaneous specified neoplasms, NOS	538	1.9	1.7*	231	2.1	1.7*
10. Unspecified malignant neoplasms	211	0.7	-0.3	75	0.7	-0.3

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

<sup>b</sup> Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

<sup>c</sup> The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1976-2005.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

\* The AAPC is significantly different from zero (p<.05).

Table XXXII-12

SEER INCIDENCE<sup>a</sup> AND U.S. MORTALITY<sup>b</sup> RATE COMPARISON BY RACE/ETHNICITY, 2001-2005  
Ages 15-19

Males	Incidence					Mortality				
	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>
All Malignant Cancers	22.7	24.7	14.1	17.4	21.8	4.1	4.3	3.9	3.0	5.3
Leukemia	3.8	4.3	2.0	2.8	5.6	1.2	1.3	1.0	-	2.1
Lymphoma	5.1	5.4	4.1	3.6	4.1	0.4	0.4	0.4	-	0.5
Hodgkin Lymphoma	2.8	3.1	1.7	2.1	2.2	0.1	0.1	-	-	-
Non-Hodgkin Lymphoma	2.3	2.4	2.4	1.4	1.9	0.3	0.3	0.4	-	0.4
Brain and Other Nervous System	2.3	2.5	1.8	1.8	1.9	0.6	0.7	0.5	-	0.7
Bones and Joints	1.9	2.0	1.7	1.8	1.8	0.7	0.7	0.5	-	0.7
Soft Tissue including Heart	1.2	1.2	1.0	1.4	1.2	0.3	0.3	0.5	-	0.3
Skin excluding Basal and Squamous	1.6	1.9	-	-	-	0.0	0.1	-	-	-
Respiratory System	0.6	0.5	-	-	0.6	0.0	0.0	-	-	-
Male Genital System	3.7	4.4	-	1.7	4.1	0.1	0.1	-	-	-
Digestive System	0.6	0.6	-	-	-	0.2	0.2	0.3	-	-

  

Females	Incidence					Mortality				
	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>
All Malignant Cancers	19.7	21.2	13.1	15.1	16.6	2.8	2.9	2.9	2.1	2.7
Leukemia	2.1	2.2	1.8	1.9	2.7	0.8	0.8	0.8	0.9	1.0
Lymphoma	4.3	4.6	3.6	3.2	3.3	0.2	0.2	0.4	-	-
Hodgkin Lymphoma	3.1	3.4	2.2	-	2.3	0.1	0.1	-	-	-
Non-Hodgkin Lymphoma	1.3	1.2	1.4	1.9	1.0	0.2	0.1	0.3	-	-
Brain and Other Nervous System	1.9	2.0	1.1	1.8	1.6	0.4	0.5	0.4	-	0.4
Bones and Joints	1.2	1.3	-	-	1.1	0.4	0.4	0.3	-	0.4
Soft Tissue including Heart	1.0	1.1	0.9	-	1.1	0.3	0.3	0.3	-	0.3
Skin excluding Basal and Squamous	2.4	2.8	-	-	-	0.0	0.0	-	-	-
Respiratory System	0.2	0.3	-	-	-	0.0	-	-	-	-
Breast	0.2	-	-	-	-	-	-	-	-	-
Female Genital System	1.9	1.9	1.6	1.6	2.6	0.1	0.1	-	-	-
Digestive System	0.5	0.6	-	-	0.7	0.1	0.1	-	-	-

Rates are per 100,000.

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> US Mortality Files, National Center for Health Statistics, CDC.

<sup>c</sup> Asian/Pacific Islander

<sup>d</sup> Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky. Mortality data for Hispanics exclude deaths from Minnesota, New Hampshire and North Dakota.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table XXXII-13

SEER INCIDENCE<sup>a</sup> AND U.S. MORTALITY<sup>b</sup> RATE COMPARISON BY RACE/ETHNICITY, 2001-2005  
Ages 20-24

Males	Incidence					Mortality				
	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>
All Malignant Cancers	32.3	35.5	19.2	19.4	27.6	5.5	5.5	5.9	4.4	5.3
Leukemia	2.9	3.0	2.6	2.6	3.9	1.4	1.4	1.2	1.0	1.9
Lymphoma	6.9	7.3	5.5	5.5	4.4	0.8	0.8	0.9	-	0.7
Hodgkin Lymphoma	4.0	4.4	2.5	2.5	2.1	0.2	0.3	0.2	-	-
Non-Hodgkin Lymphoma	2.9	2.8	2.9	3.0	2.3	0.5	0.5	0.7	-	0.6
Brain and Other Nervous System	2.3	2.6	1.5	-	1.9	0.6	0.7	0.5	-	0.4
Bones and Joints	1.1	1.2	-	-	1.3	0.6	0.6	0.6	-	0.4
Soft Tissue including Heart	1.3	1.3	1.3	-	0.9	0.4	0.4	0.5	-	0.3
Skin excluding Basal and Squamous	2.9	3.4	-	-	0.7	0.2	0.2	-	-	-
Respiratory System	0.7	0.8	-	-	0.9	0.1	0.1	-	-	0.2
Male Genital System	9.5	11.3	2.0	3.3	9.7	0.3	0.3	0.2	-	0.5
Digestive System	1.4	1.5	1.1	-	1.6	0.5	0.4	0.8	0.8	0.3

  

Females	Incidence					Mortality				
	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>
All Malignant Cancers	35.4	37.9	25.2	24.4	26.0	4.0	4.0	4.3	3.2	3.7
Leukemia	1.8	1.9	1.5	1.3	2.0	0.9	0.9	0.7	-	1.1
Lymphoma	6.3	6.7	6.0	3.9	3.7	0.6	0.6	0.8	-	0.5
Hodgkin Lymphoma	4.5	4.9	3.4	2.5	2.4	0.3	0.3	0.3	-	-
Non-Hodgkin Lymphoma	1.9	1.7	2.7	1.3	1.4	0.3	0.3	0.5	-	0.3
Brain and Other Nervous System	2.1	2.4	1.1	1.3	1.5	0.5	0.5	0.4	-	0.3
Bones and Joints	0.8	0.9	-	-	1.0	0.3	0.3	0.2	-	0.3
Soft Tissue including Heart	1.1	1.1	1.8	-	1.0	0.3	0.3	0.4	-	0.3
Skin excluding Basal and Squamous	6.3	7.5	1.0	-	1.3	0.1	0.2	-	-	-
Respiratory System	0.5	0.5	-	-	0.6	0.1	0.1	-	-	-
Breast	1.4	1.3	1.9	-	1.2	0.1	0.1	0.2	-	-
Female Genital System	4.0	3.9	4.0	4.2	4.1	0.4	0.4	0.5	-	0.3
Digestive System	1.5	1.5	1.6	1.3	1.4	0.4	0.4	0.4	0.6	0.4

Rates are per 100,000.

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> US Mortality Files, National Center for Health Statistics, CDC.

<sup>c</sup> Asian/Pacific Islander

<sup>d</sup> Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky. Mortality data for Hispanics exclude deaths from Minnesota, New Hampshire and North Dakota.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table XXXII-14

SEER INCIDENCE<sup>a</sup> AND U.S. MORTALITY<sup>b</sup> RATE COMPARISON BY RACE/ETHNICITY, 2001-2005  
Ages 25-29

Males	Incidence					Mortality				
	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>
All Malignant Cancers	45.1	48.7	32.4	26.7	32.5	7.0	7.0	8.2	5.4	5.3
Leukemia	2.7	2.8	2.9	2.2	3.2	1.2	1.2	1.4	1.0	1.3
Lymphoma	8.1	8.4	9.7	4.7	4.9	1.0	1.0	1.6	0.7	0.8
Hodgkin Lymphoma	4.1	4.5	3.9	1.6	1.9	0.4	0.3	0.7	-	0.2
Non-Hodgkin Lymphoma	4.0	3.9	5.8	3.2	3.0	0.7	0.6	1.0	0.6	0.6
Brain and Other Nervous System	3.0	3.3	1.4	2.0	2.2	0.9	1.0	0.6	-	0.5
Bones and Joints	0.6	0.6	-	-	0.5	0.3	0.4	0.3	-	0.2
Soft Tissue including Heart	1.6	1.6	1.8	-	1.4	0.4	0.4	0.5	-	0.3
Skin excluding Basal and Squamous	5.4	6.4	-	-	1.1	0.5	0.6	-	-	-
Respiratory System	1.1	1.0	1.5	-	0.8	0.2	0.2	0.3	-	0.2
Male Genital System	12.6	15.0	2.6	3.7	10.6	0.4	0.5	0.3	-	0.5
Digestive System	3.6	3.4	2.9	5.2	3.3	1.1	0.9	1.6	1.6	0.9

  

Females	Incidence					Mortality				
	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>
All Malignant Cancers	61.1	65.6	45.8	40.2	45.6	6.6	6.3	9.3	4.2	5.4
Leukemia	2.0	2.1	1.6	1.9	2.1	0.9	0.8	1.1	0.8	0.9
Lymphoma	7.3	7.7	7.0	4.5	5.2	0.8	0.7	1.4	-	0.5
Hodgkin Lymphoma	4.4	4.8	4.1	2.4	2.8	0.3	0.3	0.5	-	-
Non-Hodgkin Lymphoma	2.9	2.9	2.9	2.1	2.3	0.4	0.4	0.9	-	0.4
Brain and Other Nervous System	2.7	3.0	1.5	1.6	1.8	0.6	0.7	0.4	-	0.4
Bones and Joints	0.6	0.7	-	-	-	0.2	0.2	-	-	-
Soft Tissue including Heart	1.1	1.1	1.7	-	1.0	0.3	0.3	0.6	-	0.2
Skin excluding Basal and Squamous	10.1	12.5	1.0	-	2.9	0.3	0.4	-	-	-
Respiratory System	0.7	0.8	-	-	0.5	0.2	0.2	-	-	0.3
Breast	7.8	7.6	10.2	5.8	6.8	0.7	0.6	1.7	-	0.6
Female Genital System	9.8	10.2	9.5	6.3	10.0	1.0	0.9	1.7	-	0.9
Digestive System	3.0	3.0	2.5	3.0	2.4	0.8	0.8	1.1	0.8	0.8

Rates are per 100,000.

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> US Mortality Files, National Center for Health Statistics, CDC.

<sup>c</sup> Asian/Pacific Islander

<sup>d</sup> Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky. Mortality data for Hispanics exclude deaths from Minnesota, New Hampshire and North Dakota.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table XXXII-15

SEER INCIDENCE<sup>a</sup> AND U.S. MORTALITY<sup>b</sup> RATE COMPARISON BY RACE/ETHNICITY, 2001-2005  
Ages 30-34

Males	Incidence					Mortality				
	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>
All Malignant Cancers	60.8	64.9	47.9	36.6	42.4	10.8	10.7	13.4	8.5	7.9
Leukemia	3.3	3.4	3.4	2.7	3.4	1.4	1.5	1.7	0.8	1.7
Lymphoma	9.4	9.7	10.7	5.1	6.5	1.3	1.3	2.4	0.7	0.9
Hodgkin Lymphoma	3.8	4.1	3.5	1.7	2.1	0.4	0.4	0.6	-	0.2
Non-Hodgkin Lymphoma	5.6	5.7	7.2	3.5	4.4	0.9	0.8	1.8	0.6	0.7
Brain and Other Nervous System	3.6	4.1	1.8	2.0	2.5	1.4	1.6	0.9	0.9	0.6
Bones and Joints	0.5	0.6	-	-	0.5	0.2	0.2	0.3	-	0.2
Soft Tissue including Heart	1.9	1.8	2.8	1.0	1.6	0.5	0.5	0.8	-	0.4
Skin excluding Basal and Squamous	8.0	9.3	1.6	1.1	1.7	0.8	0.9	0.2	-	0.2
Respiratory System	1.8	1.8	1.9	2.2	1.6	0.7	0.7	0.7	0.7	0.4
Male Genital System	13.2	15.7	3.7	4.2	9.6	0.4	0.5	-	-	0.5
Digestive System	7.2	6.8	7.8	8.5	6.0	2.4	2.1	3.8	3.1	1.7

  

Females	Incidence					Mortality				
	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>
All Malignant Cancers	102.9	108.2	87.5	75.3	80.8	13.0	12.4	18.0	9.7	9.8
Leukemia	2.6	2.6	2.6	2.2	3.4	1.0	1.0	1.2	0.8	1.0
Lymphoma	7.6	8.0	8.4	4.4	5.3	0.9	0.9	1.4	0.5	0.8
Hodgkin Lymphoma	3.8	4.3	3.5	1.3	2.1	0.4	0.4	0.6	-	0.2
Non-Hodgkin Lymphoma	3.8	3.7	4.9	3.0	3.2	0.6	0.5	0.8	-	0.5
Brain and Other Nervous System	2.8	3.0	1.9	2.1	2.2	0.9	1.0	0.5	0.5	0.5
Bones and Joints	0.6	0.7	-	-	0.9	0.2	0.2	-	-	-
Soft Tissue including Heart	1.5	1.5	1.8	-	1.4	0.4	0.4	0.5	-	0.3
Skin excluding Basal and Squamous	13.1	15.8	1.8	2.2	4.2	0.5	0.6	-	-	-
Respiratory System	1.5	1.5	1.2	1.5	0.9	0.5	0.6	0.5	0.6	0.3
Breast	26.1	25.8	31.3	22.4	20.1	3.3	2.9	6.6	1.8	2.3
Female Genital System	18.8	19.6	17.2	13.6	18.7	2.3	2.3	2.9	1.6	1.9
Digestive System	6.4	6.2	7.1	6.9	6.3	1.8	1.7	2.5	2.5	1.8

Rates are per 100,000.

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> US Mortality Files, National Center for Health Statistics, CDC.

<sup>c</sup> Asian/Pacific Islander

<sup>d</sup> Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky. Mortality data for Hispanics exclude deaths from Minnesota, New Hampshire and North Dakota.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table XXXII-16

SEER INCIDENCE<sup>a</sup> AND U.S. MORTALITY<sup>b</sup> RATE COMPARISON BY RACE/ETHNICITY, 2001-2005  
Ages 35-39

Males	Incidence					Mortality				
	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>
All Malignant Cancers	88.1	91.3	83.6	56.3	61.9	19.1	18.8	23.2	15.5	12.8
Leukemia	4.2	4.2	4.1	4.2	4.3	1.6	1.5	2.1	1.4	1.7
Lymphoma	12.6	12.6	17.1	6.5	10.2	1.8	1.7	2.4	0.9	1.3
Hodgkin Lymphoma	3.5	3.8	3.7	1.5	2.3	0.4	0.4	0.5	-	0.2
Non-Hodgkin Lymphoma	9.1	8.9	13.4	5.0	7.9	1.4	1.4	2.0	0.8	1.1
Brain and Other Nervous System	4.0	4.5	2.5	1.9	3.3	2.1	2.4	1.1	0.9	1.0
Bones and Joints	0.8	0.8	-	-	0.8	0.2	0.3	-	-	0.2
Soft Tissue including Heart	2.2	2.2	3.1	1.3	2.2	0.6	0.6	0.7	-	0.4
Skin excluding Basal and Squamous	11.3	13.3	1.8	-	2.3	1.2	1.4	0.4	-	0.3
Respiratory System	4.3	4.3	4.5	4.3	2.3	2.7	2.6	3.6	2.2	1.1
Male Genital System	12.2	14.1	4.9	3.4	7.9	0.5	0.5	0.4	-	0.4
Digestive System	15.3	14.1	19.4	19.2	12.8	5.4	5.0	7.9	6.8	4.5

  

Females	Incidence					Mortality				
	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>	All Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>
All Malignant Cancers	163.4	168.2	148.0	131.3	132.8	26.3	25.2	36.9	16.4	20.0
Leukemia	2.9	3.0	2.4	2.4	2.8	1.3	1.4	1.3	0.9	1.3
Lymphoma	8.3	8.5	10.3	4.4	6.1	1.1	1.0	1.4	0.6	0.8
Hodgkin Lymphoma	2.8	3.0	2.6	1.2	1.5	0.3	0.3	0.3	-	-
Non-Hodgkin Lymphoma	5.5	5.4	7.7	3.3	4.6	0.8	0.7	1.1	-	0.7
Brain and Other Nervous System	3.4	4.0	1.9	1.6	2.8	1.4	1.5	0.8	-	0.8
Bones and Joints	0.5	0.6	-	-	0.7	0.1	0.1	0.3	-	-
Soft Tissue including Heart	2.0	1.9	2.3	1.6	2.1	0.4	0.4	0.5	-	0.4
Skin excluding Basal and Squamous	15.6	18.8	1.5	1.6	4.9	0.8	1.0	-	-	-
Respiratory System	4.5	4.4	5.3	3.7	2.1	2.5	2.6	2.8	1.5	0.7
Breast	58.9	58.4	64.3	54.9	46.1	8.2	7.3	14.9	4.7	5.9
Female Genital System	27.0	27.7	24.8	22.8	30.0	4.2	4.1	5.6	2.3	4.1
Digestive System	12.0	11.5	13.5	12.7	12.7	3.7	3.4	5.4	4.1	3.8

Rates are per 100,000.

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> US Mortality Files, National Center for Health Statistics, CDC.

<sup>c</sup> Asian/Pacific Islander

<sup>d</sup> Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky. Mortality data for Hispanics exclude deaths from Minnesota, New Hampshire and North Dakota.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table XXXII-17

SEER INCIDENCE<sup>a</sup> AND U.S. MORTALITY<sup>b</sup> RATES AND TRENDS FOR THE TOP 5 CANCER SITES<sup>c</sup> BY AGE  
All Races, Both Sexes, 1976-2005

	<u>Incidence</u>				<u>Mortality</u>			
	<u>1976-2005</u>		<u>1996-2005</u>		<u>1976-2005</u>		<u>1996-2005</u>	
	<u>Rate</u>	<u>AAPC<sup>d</sup></u>	<u>Rate</u>	<u>AAPC<sup>d</sup></u>	<u>Rate</u>	<u>AAPC<sup>d</sup></u>	<u>Rate</u>	<u>AAPC<sup>d</sup></u>
<u>Ages 15-19</u>								
All Malignant Cancers	20.1	0.5*	20.9	0.5*	4.4	-1.8*	3.6	-0.6
Hodgkin Lymphoma	3.5	-0.9*	3.1	-0.9*	0.2	-4.6*	0.1	-4.6*
Brain and Other Nervous System	2.0	0.3	2.1	0.3	0.6	-1.1*	0.5	-1.1*
Thyroid	1.6	1.0*	1.8	1.0*	0.0	-	-	-
Non-Hodgkin Lymphoma	1.6	1.5*	1.8	1.5*	0.4	-2.5*	0.3	-2.5*
Testis	1.5	1.3*	1.7	1.3*	0.1	-5.6*	0.0	-2.1
<u>Ages 20-24</u>								
All Malignant Cancers	33.4	0.8*	36.0	0.8*	5.7	-1.4*	5.0	-1.1*
Hodgkin Lymphoma	5.0	0.7	4.8	2.8*	0.5	-3.7*	0.3	-4.4*
Testis	4.3	1.7*	4.8	3.7*	0.3	-5.8*	0.2	-3.5*
Melanoma of the Skin	4.1	1.6*	4.9	1.6*	0.2	-3.2*	0.2	-1.7*
Thyroid	3.9	1.5*	4.6	1.5*	0.0	-	0.0	-
Brain and Other Nervous System	2.2	0.9*	2.4	0.9*	0.6	-0.9*	0.6	-0.9*
<u>Ages 25-29</u>								
All Malignant Cancers	54.0	0.8*	56.5	0.9	8.6	-1.6*	7.2	-1.6*
Melanoma of the Skin	7.2	1.3*	8.3	1.3*	0.5	-2.2	0.4	0.9
Testis	6.1	1.6*	6.5	1.9	0.3	-4.9*	0.2	-3.4*
Thyroid	5.9	2.0*	7.8	4.3*	0.0	-	0.0	-
Hodgkin Lymphoma	4.8	0.1	4.8	0.1	0.6	-4.0*	0.4	-4.0*
Breast	4.0	-0.5*	3.8	-0.5*	0.6	-2.2*	0.4	-2.2*
<u>Ages 30-34</u>								
All Malignant Cancers	83.5	0.8*	84.3	0.3	15.1	-1.6*	12.7	-2.5*
Breast	13.2	-0.2	13.2	-0.2	2.2	-2.1*	1.8	-2.6*
Melanoma of the Skin	10.3	0.9	10.9	2.0	0.9	-2.7*	0.7	-4.0*
Thyroid	7.5	1.8*	9.5	4.4*	0.0	-2.1*	0.0	-2.1*
Testis	6.3	2.0*	7.1	0.2	0.3	-3.8*	0.2	-3.8*
Cervix Uteri	6.0	-1.9*	5.4	-0.9*	0.9	-1.9*	0.8	-3.4*
<u>Ages 35-39</u>								
All Malignant Cancers	130.5	0.5*	129.4	0.1	28.5	-1.7*	24.3	-2.9*
Breast	31.5	0.1	30.8	-0.6*	5.4	-1.6*	4.4	-3.1*
Melanoma of the Skin	13.7	1.5*	14.4	0.1	1.4	-2.7*	1.1	-4.4*
Thyroid	8.9	3.6*	11.7	6.9*	0.1	-0.3	0.1	-0.3
Non-Hodgkin Lymphoma	8.0	2.8*	8.0	-2.1	1.7	-1.6*	1.4	-9.0*
Cervix Uteri	7.3	-1.7*	6.1	-1.7*	1.5	-1.7*	1.3	-3.2*

Rates are per 100,000.

<sup>a</sup> SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

<sup>b</sup> US Mortality Files, National Center for Health Statistics, CDC.

<sup>c</sup> Top 5 cancer sites selected based on 1976-2005 SEER 9 Incidence rates for the age group.

<sup>d</sup> The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1976-2005.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

\* The AAPC is significantly different from zero (p<.05).



Table XXXII-18

SEER INCIDENCE<sup>a</sup> AND U.S. MORTALITY<sup>b</sup> RATES AND TRENDS FOR THE TOP 5 CANCER SITES<sup>c</sup> BY AGE  
All Races, Males, 1976-2005

	<u>Incidence</u>				<u>Mortality</u>			
	<u>1976-2005</u>		<u>1996-2005</u>		<u>1976-2005</u>		<u>1996-2005</u>	
	<u>Rate</u>	<u>AAPC<sup>d</sup></u>	<u>Rate</u>	<u>AAPC<sup>d</sup></u>	<u>Rate</u>	<u>AAPC<sup>d</sup></u>	<u>Rate</u>	<u>AAPC<sup>d</sup></u>
<u>Ages 15-19</u>								
All Malignant Cancers	20.8	0.7*	22.0	0.7*	5.1	-1.9*	4.2	-0.3
Hodgkin Lymphoma	3.3	-1.0*	2.9	-1.0*	0.2	-4.9*	0.1	-4.9*
Testis	3.0	1.2*	3.4	1.2*	0.2	-5.7*	0.1	-2.2
Brain and Other Nervous System	2.3	0.4	2.4	0.4	0.7	-0.9*	0.6	-0.9*
Non-Hodgkin Lymphoma	2.0	1.5*	2.2	1.5*	0.5	-2.6*	0.4	-2.6*
Bones and Joints	1.9	0.3	1.9	0.3	0.7	-1.3*	0.6	1.0
<u>Ages 20-24</u>								
All Malignant Cancers	32.6	0.5*	33.9	0.5*	6.8	-1.7*	5.8	-1.7*
Testis	8.6	1.2	9.4	3.1	0.5	-5.9*	0.3	-3.6*
Hodgkin Lymphoma	5.0	-0.4	4.6	-0.4	0.5	-4.4*	0.3	-4.4*
Melanoma of the Skin	2.8	0.6	3.1	0.6	0.3	-3.3*	0.2	-3.3*
Brain and Other Nervous System	2.6	0.3	2.6	0.3	0.7	-0.8*	0.7	-0.8*
Non-Hodgkin Lymphoma	2.5	1.9*	3.0	1.9*	0.7	-1.1*	0.6	-1.1*
<u>Ages 25-29</u>								
All Malignant Cancers	49.1	1.0*	48.9	0.1	9.1	-1.8*	7.4	-1.8*
Testis	12.2	1.5*	12.9	1.7	0.7	-5.0*	0.4	-3.5*
Melanoma of the Skin	5.2	0.3	5.6	0.3	0.6	-2.5*	0.4	1.9
Hodgkin Lymphoma	5.0	-0.3	4.7	-0.3	0.7	-4.5*	0.4	-4.5*
Kaposi sarcoma	4.5	-	1.5	-	0.0	-	0.0	-
Non-Hodgkin Lymphoma	4.4	1.5	4.2	-3.0	1.0	-1.7*	0.8	-7.5*
<u>Ages 30-34</u>								
All Malignant Cancers	70.8	1.2*	66.1	-1.5	14.1	-1.6*	11.7	-3.0*
Testis	12.6	2.0*	14.0	0.3	0.6	-3.9*	0.4	-3.9*
Kaposi sarcoma	10.0	-	3.9	-	0.0	-	0.0	-
Melanoma of the Skin	8.3	-0.1	8.0	-0.1	1.1	-2.0*	0.8	-1.2
Non-Hodgkin Lymphoma	7.5	2.1*	7.1	-8.4*	1.6	-1.6*	1.3	-11.5*
Hodgkin Lymphoma	4.2	-0.2	4.0	-0.2	0.8	-4.3*	0.5	-6.3*
<u>Ages 35-39</u>								
All Malignant Cancers	100.8	0.5	94.3	-1.1	24.9	-1.8*	20.8	-3.0*
Melanoma of the Skin	12.2	0.6	11.9	-1.2*	1.8	-3.1*	1.3	-5.9*
Kaposi sarcoma	12.0	-	4.9	-	0.0	-	0.0	-
Non-Hodgkin Lymphoma	11.1	3.4*	10.4	-3.2	2.3	-1.8*	1.8	-10.7*
Testis	10.8	2.3*	12.3	0.7	0.5	-2.9*	0.5	-1.0*
Colon and Rectum	7.1	-0.2	8.1	1.7*	2.2	-1.4	2.1	-0.2

Rates are per 100,000.

<sup>a</sup> SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

<sup>b</sup> US Mortality Files, National Center for Health Statistics, CDC.

<sup>c</sup> Top 5 cancer sites selected based on 1976-2005 rates for the age group.

<sup>d</sup> The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1976-2005.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

\* The AAPC is significantly different from zero ( $p < .05$ ).

Table XXXII-19

SEER INCIDENCE<sup>a</sup> AND U.S. MORTALITY<sup>b</sup> RATES AND TRENDS FOR THE TOP 5 CANCER SITES<sup>c</sup> BY AGE  
All Races, Females, 1976-2005

	<u>Incidence</u>				<u>Mortality</u>			
	<u>1976-2005</u>		<u>1996-2005</u>		<u>1976-2005</u>		<u>1996-2005</u>	
	<u>Rate</u>	<u>AAPC<sup>d</sup></u>	<u>Rate</u>	<u>AAPC<sup>d</sup></u>	<u>Rate</u>	<u>AAPC<sup>d</sup></u>	<u>Rate</u>	<u>AAPC<sup>d</sup></u>
<u>Ages 15-19</u>								
All Malignant Cancers	19.4	0.3*	19.7	0.3*	3.5	-1.7*	2.9	-1.7*
Hodgkin Lymphoma	3.7	-0.9*	3.3	-0.9*	0.2	-3.9*	0.1	-3.9*
Thyroid	2.8	1.1*	3.1	1.1*	0.0	-	-	-
Melanoma of the Skin	1.8	1.1*	2.0	1.1*	0.1	-3.0*	0.0	-3.0*
Brain and Other Nervous System	1.7	0.1	1.7	0.1	0.5	-1.4*	0.4	-1.4*
Ovary	1.5	0.2	1.4	0.2	0.1	-5.1*	0.1	-5.1*
<u>Ages 20-24</u>								
All Malignant Cancers	34.1	0.7	38.3	1.4*	4.7	-1.1*	4.2	-1.1*
Thyroid	6.7	1.9*	8.1	1.9*	0.0	-	-	-
Melanoma of the Skin	5.4	2.2*	6.8	2.2*	0.2	-2.9*	0.1	0.2
Hodgkin Lymphoma	5.0	1.1	5.0	-0.7	0.4	-2.7*	0.3	-2.7*
Cervix Uteri	2.2	-1.9	1.6	-1.0	0.2	-0.7	0.2	-0.7
Ovary	1.9	-1.2*	1.6	-1.2*	0.2	-1.8*	0.2	-1.8*
<u>Ages 25-29</u>								
All Malignant Cancers	59.0	0.8*	64.2	0.8*	8.1	-1.5*	7.0	-2.5*
Thyroid	9.8	2.1*	13.0	4.8*	0.0	-	0.0	-
Melanoma of the Skin	9.1	1.8*	11.0	1.8*	0.4	-2.6*	0.3	-2.6*
Breast	8.0	-0.5*	7.8	-0.5*	1.1	-2.1*	0.8	-2.1*
Cervix Uteri	7.5	-1.7	6.4	-2.9*	0.8	-1.3*	0.7	-1.3*
Hodgkin Lymphoma	4.7	0.6	4.8	0.6	0.5	-3.3*	0.3	-3.3*
<u>Ages 30-34</u>								
All Malignant Cancers	96.2	0.6*	102.8	1.6*	16.2	-1.6*	13.8	-2.6*
Breast	26.4	-0.1	26.5	-0.1	4.5	-2.0*	3.6	-2.6*
Melanoma of the Skin	12.4	1.3*	13.9	1.3*	0.7	-2.9*	0.5	-2.9*
Thyroid	12.1	2.4*	15.9	4.6*	0.0	-	0.0	-
Cervix Uteri	11.9	-1.8*	10.9	-0.8*	1.8	-1.8*	1.6	-3.3*
Hodgkin Lymphoma	3.7	1.2*	4.1	1.2*	0.5	-3.3*	0.4	-3.3*
<u>Ages 35-39</u>								
All Malignant Cancers	160.1	0.5*	164.7	0.9*	32.0	-1.5*	27.8	-2.5*
Breast	62.6	0.4	61.6	0.4	10.8	-1.5*	8.7	-3.0*
Melanoma of the Skin	15.2	2.1*	16.9	0.7*	1.1	-2.3*	0.9	-2.3*
Cervix Uteri	14.5	-1.6*	12.3	-1.6*	3.0	-1.7*	2.6	-3.1*
Thyroid	13.8	4.0*	18.7	7.1*	0.1	-0.6	0.1	-0.6
Corpus and Uterus, NOS	6.4	0.8	6.9	4.2*	0.4	-1.4	0.4	3.7

Rates are per 100,000.

<sup>a</sup> SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

<sup>b</sup> US Mortality Files, National Center for Health Statistics, CDC.

<sup>c</sup> Top 5 cancer sites selected based on 1976-2005 rates for the age group.

<sup>d</sup> The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1976-2005.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

\* The AAPC is significantly different from zero (p<.05).

Table XXXII-20

SEER 5-YEAR RELATIVE SURVIVAL RATES<sup>a</sup> FOR THE TOP 5 CANCER SITES<sup>b</sup> BY AGE  
All Races, Both Sexes, 1976-2004

	5-year Relative Survival Rate			
	1976-2004	1976-1985	1986-1995	1996-2004
<u>Ages 15-19</u>				
All Malignant Cancers	76.2	70.8	78.0	80.4
Hodgkin Lymphoma	91.4	88.7	91.9	95.0
Brain and Other Nervous System	72.6	63.7	76.3	78.7
Thyroid	98.6	98.8	99.1	97.9
Non-Hodgkin Lymphoma	68.9	55.2	71.4	78.7
Testis	89.3	83.3	91.6	92.5
<u>Ages 20-24</u>				
All Malignant Cancers	79.3	75.5	79.8	83.6
Hodgkin Lymphoma	89.5	86.4	89.6	94.0
Testis	91.9	86.8	93.7	95.6
Melanoma of the Skin	91.6	86.8	93.5	95.0
Thyroid	99.5	99.5	99.7	99.2
Brain and Other Nervous System	63.7	59.1	66.5	66.5
<u>Ages 25-29</u>				
All Malignant Cancers	77.5	76.7	73.5	83.9
Melanoma of the Skin	92.3	88.7	93.1	94.8
Testis	94.6	90.5	95.9	97.1
Thyroid	99.7	99.3	99.9	99.7
Hodgkin Lymphoma	89.2	86.3	89.7	92.5
Breast	72.4	70.2	69.3	81.1
<u>Ages 30-34</u>				
All Malignant Cancers	73.1	72.4	68.1	80.7
Breast	75.4	70.6	75.5	81.2
Melanoma of the Skin	91.4	87.2	92.2	94.6
Thyroid	99.6	99.2	99.8	99.7
Testis	95.2	91.8	96.2	96.3
Cervix Uteri	84.9	83.9	83.9	87.5
<u>Ages 35-39</u>				
All Malignant Cancers	70.9	68.0	66.8	78.3
Breast	79.8	74.6	79.9	84.5
Melanoma of the Skin	91.4	88.1	90.9	94.4
Thyroid	99.2	99.3	99.1	99.1
Non-Hodgkin Lymphoma	58.1	64.9	47.9	68.1
Cervix Uteri	81.2	78.6	81.3	84.1

Survival rates are relative rates expressed as percents.

<sup>a</sup> SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

<sup>b</sup> Top 5 cancer sites selected based on 1976-2005 rates for the age group.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XXXII-21

SEER 5-YEAR RELATIVE SURVIVAL RATES<sup>a</sup> FOR THE TOP 5 CANCER SITES<sup>b</sup> BY AGE  
All Races, Males, 1976-2004

	<u>5-year Relative Survival Rate</u>			
	<u>1976-2004</u>	<u>1976-1985</u>	<u>1986-1995</u>	<u>1996-2004</u>
<u>Ages 15-19</u>				
All Malignant Cancers	71.5	64.7	73.7	76.5
Hodgkin Lymphoma	90.4	87.7	90.5	94.6
Testis	89.3	83.3	91.6	92.5
Brain and Other Nervous System	69.8	58.6	75.1	76.3
Non-Hodgkin Lymphoma	66.5	50.7	74.2	73.5
Bones and Joints	56.5	43.1	61.5	64.5
<u>Ages 20-24</u>				
All Malignant Cancers	74.4	69.9	74.4	80.3
Testis	91.9	86.8	93.7	95.6
Hodgkin Lymphoma	87.5	83.8	87.4	93.9
Melanoma of the Skin	84.1	76.3	88.7	89.7
Brain and Other Nervous System	62.5	56.2	66.2	67.0
Non-Hodgkin Lymphoma	59.7	49.7	56.6	71.7
<u>Ages 25-29</u>				
All Malignant Cancers	70.6	70.7	64.2	80.1
Testis	94.6	90.5	95.9	97.1
Melanoma of the Skin	87.6	82.6	89.1	91.2
Hodgkin Lymphoma	87.0	85.0	85.3	92.8
Kaposi sarcoma	11.4	14.0	7.9	42.8
Non-Hodgkin Lymphoma	53.5	59.6	41.5	69.9
<u>Ages 30-34</u>				
All Malignant Cancers	63.7	65.8	55.0	76.2
Testis	95.2	91.8	96.2	96.3
Kaposi sarcoma	15.5	13.3	11.2	48.9
Melanoma of the Skin	86.6	80.4	88.4	91.2
Non-Hodgkin Lymphoma	48.4	65.0	34.3	63.4
Hodgkin Lymphoma	84.9	80.8	83.4	91.7
<u>Ages 35-39</u>				
All Malignant Cancers	59.6	58.8	51.7	71.5
Melanoma of the Skin	87.0	82.7	86.7	91.0
Kaposi sarcoma	15.0	9.5	9.7	51.6
Non-Hodgkin Lymphoma	50.3	60.3	38.8	62.1
Testis	95.7	92.9	96.0	96.8
Colon and Rectum	59.6	53.8	54.6	67.8

Survival rates are relative rates expressed as percents.

<sup>a</sup> SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

<sup>b</sup> Top 5 cancer sites selected based on 1976-2005 rates for the age group.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XXXII-22

SEER 5-YEAR RELATIVE SURVIVAL RATES<sup>a</sup> FOR THE TOP 5 CANCER SITES<sup>b</sup> BY AGE  
All Races, Females, 1976-2004

	5-year Relative Survival Rate			
	1976-2004	1976-1985	1986-1995	1996-2004
<u>Ages 15-19</u>				
All Malignant Cancers	81.4	77.4	82.7	84.8
Hodgkin Lymphoma	92.2	89.6	93.0	95.3
Thyroid	98.8	98.8	99.7	97.9
Melanoma of the Skin	93.9	87.2	95.6	98.6
Brain and Other Nervous System	76.7	70.7	78.0	82.1
Ovary	89.4	85.8	88.4	95.4
<u>Ages 20-24</u>				
All Malignant Cancers	84.2	81.3	85.2	86.7
Thyroid	99.5	99.1	99.5	99.8
Melanoma of the Skin	95.8	93.8	96.0	97.4
Hodgkin Lymphoma	91.5	89.5	91.7	94.0
Cervix Uteri	88.7	90.4	85.9	90.0
Ovary	83.2	81.1	85.5	84.0
<u>Ages 25-29</u>				
All Malignant Cancers	83.3	81.2	82.6	86.9
Thyroid	99.8	99.4	99.8	100.0
Melanoma of the Skin	95.1	92.8	95.5	96.8
Breast	72.4	70.2	69.3	81.1
Cervix Uteri	87.4	88.3	86.4	87.4
Hodgkin Lymphoma	91.7	87.8	94.7	92.1
<u>Ages 30-34</u>				
All Malignant Cancers	80.1	76.5	80.4	83.6
Breast	75.3	70.6	75.5	81.2
Melanoma of the Skin	94.6	92.3	94.8	96.6
Thyroid	99.7	99.2	99.8	99.8
Cervix Uteri	84.9	83.9	83.9	87.5
Hodgkin Lymphoma	89.9	85.9	91.1	91.8
<u>Ages 35-39</u>				
All Malignant Cancers	78.1	73.0	78.1	82.3
Breast	79.7	74.6	79.9	84.5
Melanoma of the Skin	95.0	92.8	94.7	96.9
Cervix Uteri	81.2	78.6	81.3	84.1
Thyroid	99.5	99.3	99.2	99.7
Corpus and Uterus, NOS	90.5	91.5	90.0	89.8

Survival rates are relative rates expressed as percents.

<sup>a</sup> SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

<sup>b</sup> Top 5 cancer sites selected based on 1976-2005 SEER 9 Incidence rates for the age group.

- Statistic could not be calculated due to fewer than 16 cases during the time period.